Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 1884
interventional 1444
Observational 409
Registry 31

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 805
Drug|placebo 217
Biological 197
Other 37
Behavioral 34
Biological|Drug 31
Biological|Drug|placebo 22
Biological|placebo 13
Procedure 13
Dietary Supplement 11
Device 10
Drug|Other 6
Behavioral|Other 5
Biological|Other 5
Device|Drug 5
Biological|Procedure 4
Diagnostic Test 4
Dietary Supplement|placebo 4
Other|Procedure 3
Behavioral|Biological 2
Behavioral|Drug 2
Dietary Supplement|Drug 2
Drug|Procedure 2
Behavioral|Diagnostic Test 1
Biological|Drug|Other 1
Biological|Drug|Procedure 1
Biological|Other|placebo 1
Device|Other 1
Diagnostic Test|Drug 1
Dietary Supplement|Drug|Procedure 1
Dietary Supplement|Other 1
Drug|Other|Procedure 1
Genetic 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 280
NA 211
China 106
Korea, Republic of 44
United States|Puerto Rico 42
Taiwan 39
Japan 34
France 30
Canada 27
Egypt 26
India 25
Germany 23
Belgium 22
Spain 22
United Kingdom 19
Iran, Islamic Republic of 14
Russian Federation 14
Australia 13
Brazil 13
Thailand 13
Italy 12
Netherlands 12
United States|Canada 12
Austria 8
New Zealand 8
Hong Kong 7
Vietnam 6
Australia|New Zealand 5
Belgium|France 5
Israel 5
Singapore 5
Sweden 5
China|Korea, Republic of 4
Denmark 4
Mexico 4
Poland 4
Switzerland 4
Belgium|Czech Republic|Hungary 3
Belgium|Germany 3
Norway 3
Pakistan 3
Philippines 3
Puerto Rico 3
Turkey 3
United States|France|Germany|Spain 3
United States|New Zealand 3
Australia|Hong Kong|Korea, Republic of|New Zealand|Thailand 2
Bangladesh 2
Belgium|Czechia 2
Belgium|Germany|United Kingdom 2
Belgium|Netherlands 2
Bulgaria 2
Chile 2
China|Hong Kong 2
Cuba 2
Czech Republic 2
Czech Republic|Malaysia|Spain 2
Kazakhstan 2
Moldova, Republic of 2
Philippines|Thailand 2
Rwanda 2
Saudi Arabia 2
South Africa 2
United States|Australia|Canada|Korea, Republic of|New Zealand 2
United States|Canada|Hong Kong|New Zealand|United Kingdom 2
United States|France|Puerto Rico 2
United States|New Zealand|Singapore|Taiwan 2
Algeria|Australia|Austria|Belgium|Bulgaria|Canada|Denmark|Finland|France|Germany|Greece|Ireland|Israel|Italy|Mexico|Netherlands|Norway|Poland|Portugal|Romania|Russian Federation|Saudi Arabia|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Argentina|Australia|Canada|Mexico|New Zealand|Thailand 1
Argentina|Brazil|Germany|Thailand 1
Argentina|United States|Australia|Belgium|Canada|France|Germany|Hong Kong|Hungary|Italy|Korea, Republic of|Mexico|Poland|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|Thailand|United Kingdom|Vietnam 1
Australia|Austria|United States|Canada|France|Germany|Italy|Puerto Rico|Spain 1
Australia|Belgium 1
Australia|Belgium|Spain 1
Australia|Belgium|Ukraine 1
Australia|Brazil|France|Poland|Russian Federation|Spain|Sweden|United Kingdom 1
Australia|Bulgaria|China|Hong Kong|Korea, Republic of|New Zealand|Singapore|Taiwan|Thailand 1
Australia|Canada|Czech Republic|France|Germany|Israel|Poland|Romania 1
Australia|Canada|Czechia|Finland|Italy|Spain 1
Australia|Canada|France|Germany|Greece|India|Italy|Poland|Spain|Taiwan|Thailand|United Kingdom 1
Australia|Czech Republic|Germany|Italy|Netherlands|Switzerland|United Kingdom 1
Australia|France|Germany|Italy|Spain|United Kingdom 1
Australia|Germany|Poland|Romania|Spain|Taiwan 1
Australia|Hong Kong|Korea, Republic of|New Zealand|Singapore|Taiwan|Thailand 1
Australia|Hong Kong|Korea, Republic of|Taiwan|United Kingdom 1
Australia|Hong Kong|New Zealand 1
Australia|New Zealand|United Kingdom 1
Austria|Belgium|Denmark|Iceland 1
Austria|Belgium|France|Germany|Japan|Portugal|Romania|Russian Federation|Spain|Switzerland|United Kingdom 1
Austria|Belgium|France|Germany|Netherlands|Spain 1
Austria|Belgium|France|Germany|Spain|United Kingdom 1
Austria|Brazil|France|Greece|Indonesia|Italy|Turkey|United Arab Emirates 1
Austria|Bulgaria|Germany|Greece|Italy|Russian Federation|Spain|Turkey 1
Austria|France|Germany|United Kingdom 1
Austria|Germany|Hungary|Poland|Romania|Spain 1
Belarus|India|Russian Federation|Thailand 1
Belgium|Brazil|France|Austria|United States|Australia|Germany|Ireland|Mexico|Poland|Spain|Sweden|United Kingdom 1
Belgium|Bulgaria|France|Georgia|Germany|Malaysia|Moldova, Republic of|Romania|Spain|Taiwan 1
Belgium|Canada 1
Belgium|Canada|Germany|Poland|Singapore|Spain 1
Belgium|Czech Republic 1
Belgium|Czechia|Germany 1
Belgium|France|Germany|Hungary|Spain|United Kingdom 1
Belgium|France|Germany|Italy|Poland|Romania|Spain 1
Belgium|France|Germany|Italy|Poland|Spain|United Kingdom 1
Belgium|Germany|Hungary|Ireland|Luxembourg|Portugal|Russian Federation|United Kingdom 1
Belgium|Germany|Philippines|United Kingdom 1
Belgium|Germany|Poland|United Kingdom 1
Belgium|Germany|Thailand 1
Belgium|Mauritius|Moldova, Republic of 1
Belgium|Moldova, Republic of 1
Bulgaria|China|Hong Kong|Korea, Republic of|New Zealand|Poland|Taiwan|United Kingdom 1
Bulgaria|Former Yugoslavia 1
Bulgaria|Hong Kong|Italy|Netherlands|New Zealand|Taiwan|Thailand|United Kingdom 1
Bulgaria|Israel|Romania 1
Bulgaria|Romania 1
Cambodia 1
Cameroon|Côte D’Ivoire|Senegal 1
Canada|China|France|Hong Kong|Korea, Republic of|New Zealand|Spain|Taiwan|Thailand|United Kingdom 1
Canada|France|Germany 1
Canada|Germany 1
Canada|Hong Kong|Korea, Republic of|Taiwan 1
Canada|Korea, Republic of|Taiwan 1
Canada|Moldova, Republic of|Ukraine 1
Canada|Netherlands 1
Canada|United Kingdom 1
Canada|United States|Australia|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Taiwan 1
Canada|United States|Austria|Brazil|France|Germany|Italy|Mexico|Puerto Rico|Spain|United Kingdom 1
China|France|Korea, Republic of|Singapore|Taiwan|Thailand|United States|Australia|Canada 1
China|Hong Kong|Japan|Korea, Republic of|Philippines|Singapore 1
China|Korea, Republic of|Russian Federation 1
China|Korea, Republic of|Singapore 1
China|Netherlands 1
China|Netherlands|Poland|Romania|Turkey 1
China|United Kingdom 1
China|United States|Canada|France 1
China|United States|Korea, Republic of|Singapore|Taiwan 1
Colombia 1
Congo, The Democratic Republic of the 1
Czech Republic|France|Germany|Italy|Poland|Spain|Sweden|United Kingdom 1
Czech Republic|Korea, Republic of|Mexico 1
Czechia|Slovakia 1
Czechia|United States|Belgium|Brazil|Canada|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Malaysia|Poland|Russian Federation|Spain|Thailand|Turkey|United Kingdom 1
Estonia|Latvia|Lithuania 1
Finland 1
Finland|Sweden 1
France|Belgium|Germany|Netherlands|Poland|United Kingdom 1
France|Denmark|United States|Australia|Austria|Belgium|Canada|Germany|New Zealand|Norway|Poland|Russian Federation|Spain 1
France|Georgia|Moldova, Republic of 1
France|Germany|Greece|Italy|Spain 1
France|Germany|Italy|Netherlands|Poland|Romania|Spain 1
France|Germany|United States|Canada|Italy|Puerto Rico|Spain 1
France|Italy|Spain|United Kingdom 1
France|Moldova, Republic of|Romania 1
France|Netherlands|Poland 1
France|New Zealand|Poland 1
France|Spain 1
France|Sweden|United Kingdom 1
France|United States|Australia|Austria|Belgium|Canada|Germany|New Zealand|Poland|Puerto Rico|Russian Federation|Spain|United Kingdom 1
France|United States|Australia|Bulgaria|Canada|Czech Republic|Germany|Greece|Italy|Netherlands|New Zealand|Poland|Spain|Turkey|United Kingdom 1
France|United States|Belgium|Brazil|Canada|Denmark|Germany|Hungary|Netherlands|Poland|Puerto Rico|Romania|Russian Federation|Sweden|United Kingdom 1
Germany|Greece|Romania 1
Germany|Hong Kong|Korea, Republic of|New Zealand|Singapore|United Kingdom 1
Germany|Israel|Mexico|United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|France|Netherlands|New Zealand|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Spain|Ukraine|United Kingdom 1
Germany|Netherlands 1
Germany|Poland|Spain 1
Germany|Poland|Sweden|United Kingdom 1
Germany|Russian Federation 1
Germany|Serbia|United States|Argentina|Belgium|Chile|Egypt|Estonia|France|Greece|Italy|Kuwait|Latvia|Lebanon|Lithuania|Macedonia, The Former Yugoslav Republic of|Mexico|Oman|Pakistan|Peru|Portugal|Qatar|Romania|Slovakia|Sweden|Switzerland|Syrian Arab Republic|Taiwan|Turkey|United Arab Emirates|Venezuela 1
Germany|United Kingdom 1
Germany|United States 1
Germany|United States|Australia|Austria|Canada|France|Italy|Puerto Rico|Spain|United Kingdom 1
Germany|United States|Australia|Belgium|France|Hungary|Italy|Poland|Puerto Rico|Romania|Spain|Taiwan|Turkey|United Kingdom 1
Germany|United States|Australia|Canada|France|Hong Kong|New Zealand|Poland|Singapore|Taiwan|United Kingdom 1
Germany|United States|Austria|Canada|France|Netherlands|Puerto Rico|United Kingdom 1
Hong Kong|Korea, Republic of 1
Hong Kong|Korea, Republic of|Malaysia|New Zealand|Singapore|Taiwan 1
Hong Kong|Korea, Republic of|Singapore|Taiwan|Vietnam 1
Hong Kong|New Zealand|Singapore 1
Hong Kong|Singapore|Taiwan|Thailand 1
Indonesia 1
Israel|New Zealand|Pakistan 1
Italy|Portugal|United States|Belgium|Brazil|Canada|France|Germany|Greece|Spain|Sweden|Switzerland|Turkey|United Kingdom 1
Italy|United States|Argentina|Australia|Belgium|Canada|France|Germany|Hong Kong|Hungary|India|Korea, Republic of|Mexico|Poland|Romania|Russian Federation|Spain|Taiwan|Thailand|Turkey|United Kingdom|Vietnam 1
Italy|United States|Australia|Belgium|Bulgaria|China|Germany|Israel|Poland|Russian Federation|Ukraine|United Kingdom 1
Korea, Republic of|Moldova, Republic of|New Zealand|Thailand|Ukraine 1
Korea, Republic of|Russian Federation|Taiwan 1
Korea, Republic of|Taiwan 1
Korea, Republic of|Taiwan|Thailand 1
Korea, Republic of|United Kingdom 1
Lao People’s Democratic Republic|Thailand 1
Lebanon 1
Mauritius|United Kingdom 1
Morocco 1
Myanmar 1
Nepal 1
Panama 1
Romania 1
Russian Federation|Sweden 1
Russian Federation|United States|Argentina|Australia|Belgium|Chile|Finland|France|Greece|Hong Kong|Italy|Japan|Korea, Republic of|Mexico|Netherlands|New Zealand|Singapore|Taiwan|United Kingdom 1
Slovakia 1
Spain|Sweden|Puerto Rico|Poland|United States|Australia|Austria|Belgium|Brazil|Canada|France|Germany|Israel|Netherlands|Switzerland|United Kingdom 1
Spain|Switzerland|United Kingdom 1
Thailand|Australia|Brazil|China|Hong Kong|Korea, Republic of|New Zealand|Russian Federation|Singapore|Taiwan 1
Turkey|United States|Austria|Bulgaria|Canada|Czech Republic|Germany|Greece|Hungary|New Zealand|Poland|Romania|Serbia|Spain 1
United Kingdom|Australia|Canada|Israel|New Zealand|Spain 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Bulgaria|Canada|Czech Republic|Denmark|France|Germany|Greece|Hungary|Israel|Norway|Poland|Portugal|Puerto Rico|Romania|Spain|Sweden|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Brazil|Canada|Denmark|France|Germany|Israel|Italy|Poland|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Argentina|Australia|Austria|Canada|Denmark|France|Germany|Greece|Ireland|Italy|Korea, Republic of|Mexico|New Zealand|Poland|Spain|Sweden|Taiwan|United Kingdom 1
United States|Argentina|Australia|Austria|Canada|France|Germany|Israel|Italy|Poland|Puerto Rico|Spain|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|France|Germany|Italy|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Argentina|Australia|Brazil|Canada|France|India|Italy|Mexico|Poland|Russian Federation|South Africa|Turkey 1
United States|Argentina|Australia|Brazil|France|Italy|Korea, Republic of|Spain|Taiwan 1
United States|Argentina|Australia|Canada|France|Israel|Italy|Poland|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Argentina|Austria|Belgium|Brazil|Bulgaria|France|Germany|Netherlands|Poland|Portugal|Puerto Rico|Slovakia|Spain|Turkey 1
United States|Argentina|Belgium|Brazil|Canada|Korea, Republic of|Taiwan|United Kingdom 1
United States|Argentina|Belgium|Canada|Germany|Greece|India|Israel|Korea, Republic of|Poland|Romania|Russian Federation|Taiwan|United Kingdom 1
United States|Argentina|Canada|Puerto Rico 1
United States|Argentina|France|Germany|Hungary|Spain 1
United States|Australia|Austria|Belgium|Brazil|Canada|Germany|Mexico|Puerto Rico|Switzerland 1
United States|Australia|Austria|Belgium|Canada|France|Germany|Israel|New Zealand|Norway|Poland|Portugal|Russian Federation|United Kingdom 1
United States|Australia|Austria|Brazil|Canada|France|Germany|Italy|Mexico|Poland|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Austria|Canada|France|Germany|Italy 1
United States|Australia|Belgium|Brazil|Canada|Czech Republic|France|Germany|Hong Kong|India|Israel|Italy|Korea, Republic of|Netherlands|Pakistan|Poland|Puerto Rico|Romania|Russian Federation|Slovakia|Spain|Taiwan|Thailand|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Greece|Italy|New Zealand|Portugal|Spain|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|India|Italy|Korea, Republic of|Poland|Puerto Rico|Taiwan|Thailand|United Kingdom 1
United States|Australia|Belgium|Canada|France|New Zealand|Singapore|South Africa|Vietnam 1
United States|Australia|Belgium|Canada|Germany|New Zealand|Puerto Rico|United Kingdom 1
United States|Australia|Belgium|Germany|Italy|Malaysia|Romania|Russian Federation|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Belgium|Germany|Puerto Rico|Spain|Taiwan 1
United States|Australia|Brazil|Canada|China|France|Germany|Israel|Korea, Republic of|New Zealand|Poland|Puerto Rico|Singapore|Switzerland|Taiwan|Thailand|United Kingdom 1
United States|Australia|Brazil|Canada|China|Germany|Korea, Republic of|New Zealand|Russian Federation|Spain|Sweden|Switzerland|United Kingdom 1
United States|Australia|Brazil|Canada|Greece|Hong Kong|India|Indonesia|Italy|Korea, Republic of|Malaysia|Philippines|Poland|Russian Federation|Singapore|Taiwan|Thailand|Turkey 1
United States|Australia|Brazil|China|France|Germany|Hong Kong|Korea, Republic of|New Zealand|Russian Federation|Singapore|Taiwan|Thailand 1
United States|Australia|Brazil|France|Greece|Italy|Poland|Puerto Rico|Spain|Taiwan|United Kingdom 1
United States|Australia|Bulgaria|Canada|Czech Republic|France|Germany|Greece|Italy|Netherlands|New Zealand|Poland|Spain|Turkey|United Kingdom 1
United States|Australia|Canada|China|France|Germany|India|Israel|Korea, Republic of|Latvia|Malaysia|New Zealand|Poland|Russian Federation|Singapore|Spain|Taiwan|Thailand|Turkey|United Kingdom|Vietnam 1
United States|Australia|Canada|China|France|Israel|New Zealand|Singapore|Taiwan|Thailand|United Kingdom 1
United States|Australia|Canada|Denmark|France|Italy 1
United States|Australia|Canada|France 1
United States|Australia|Canada|France|Germany|Greece|Hong Kong|India|Italy|Korea, Republic of|Netherlands|Poland|Portugal|Romania|Singapore|Spain|Taiwan|Turkey|United Kingdom 1
United States|Australia|Canada|France|Germany|Greece|Italy|Pakistan|Spain 1
United States|Australia|Canada|France|Germany|Italy|New Zealand|Puerto Rico|Spain 1
United States|Australia|Canada|France|Germany|New Zealand|Puerto Rico|Spain|United Kingdom 1
United States|Australia|Canada|France|Germany|New Zealand|Switzerland|United Kingdom 1
United States|Australia|Canada|France|New Zealand|Poland|Slovakia 1
United States|Australia|Canada|France|Puerto Rico 1
United States|Australia|Canada|Germany|Mexico|New Zealand|Puerto Rico|Romania|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|Australia|Canada|Germany|Netherlands|New Zealand|Switzerland|United Kingdom 1
United States|Australia|Canada|New Zealand 1
United States|Australia|Canada|New Zealand|Puerto Rico 1
United States|Australia|Canada|New Zealand|United Kingdom 1
United States|Australia|China|Hong Kong|Korea, Republic of|New Zealand|United Kingdom 1
United States|Australia|Germany|New Zealand|Poland 1
United States|Australia|Hong Kong|New Zealand|Philippines|Singapore|Taiwan|Thailand 1
United States|Australia|New Zealand 1
United States|Australia|Puerto Rico 1
United States|Austria|Belgium|Canada|Czech Republic|France|Germany|Italy|Poland|Spain|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Japan|Korea, Republic of|Portugal|Romania|Russian Federation|Spain|Switzerland|Taiwan|United Kingdom 1
United States|Austria|Belgium|Canada|France|Germany|Japan|Portugal|Puerto Rico|Spain|Switzerland|United Kingdom 1
United States|Austria|Belgium|Canada|France|Switzerland|United Kingdom 1
United States|Austria|Belgium|France|Germany|Netherlands|Poland|United Kingdom 1
United States|Austria|Canada|France|Germany|Romania 1
United States|Austria|Canada|France|Germany|Spain 1
United States|Belgium 1
United States|Belgium|Brazil|Canada|Colombia|France|Germany|Italy|Korea, Republic of|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Belgium|Bulgaria|France|Germany|Puerto Rico 1
United States|Belgium|Canada|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Malaysia|Poland|Russian Federation|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Belgium|Canada|Czechia|Denmark|Germany|Japan|Netherlands|Spain|Sweden|Switzerland|United Kingdom 1
United States|Belgium|Canada|France|Germany|Hungary|Korea, Republic of|Puerto Rico|Spain 1
United States|Belgium|Canada|France|Germany|Poland|Russian Federation 1
United States|Belgium|Canada|Germany|Japan|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Belgium|Canada|Hong Kong|India|Korea, Republic of|New Zealand|Romania|Russian Federation|Taiwan 1
United States|Belgium|Germany|Italy|Taiwan 1
United States|Belgium|Germany|Puerto Rico|Spain 1
United States|Belgium|Netherlands|Puerto Rico 1
United States|Brazil|Canada|France|Greece|Hong Kong|India|Indonesia|Philippines|Poland|Russian Federation|Singapore|South Africa|Taiwan|Thailand|Turkey|United Kingdom 1
United States|Brazil|France|Germany|Italy|Spain|Switzerland|United Kingdom 1
United States|Brazil|France|New Zealand|Sweden 1
United States|Brazil|Mexico|Puerto Rico|South Africa 1
United States|Brazil|South Africa 1
United States|Bulgaria|Canada|Czechia|France|Greece|Hungary|Ireland|Israel|Italy|Poland|Portugal|Puerto Rico|Romania|Russian Federation|Spain|Taiwan|United Kingdom|Vietnam 1
United States|Bulgaria|Canada|France|Germany|Poland|Puerto Rico|Russian Federation|Spain|United Kingdom 1
United States|Bulgaria|France|Poland|Romania|Spain|Turkey 1
United States|Canada|France|Germany|Greece|Italy|Poland|Singapore|Spain|Taiwan|Turkey 1
United States|Canada|France|Germany|Italy|Spain|United Kingdom 1
United States|Canada|France|Germany|Portugal|Puerto Rico|Spain|United Kingdom 1
United States|Canada|Germany 1
United States|Canada|Germany|Greece|Italy|Korea, Republic of|Poland|Puerto Rico|Spain|Sweden 1
United States|Canada|Germany|Netherlands|Puerto Rico 1
United States|Canada|Germany|Poland|United Kingdom 1
United States|Canada|Hong Kong|Indonesia|Philippines|Singapore|Taiwan|Thailand 1
United States|Canada|Hong Kong|Italy|Korea, Republic of|New Zealand|Taiwan|United Kingdom 1
United States|Canada|Hong Kong|Italy|Korea, Republic of|Spain|Taiwan|United Kingdom 1
United States|Canada|Italy|Korea, Republic of|Netherlands|New Zealand 1
United States|Canada|Italy|Korea, Republic of|New Zealand|Romania 1
United States|Canada|Korea, Republic of|Puerto Rico|Taiwan 1
United States|Canada|New Zealand 1
United States|Canada|United Kingdom 1
United States|Czechia|France|Germany|Hungary|Poland|Puerto Rico|Spain|United Kingdom 1
United States|France 1
United States|France|Germany|New Zealand 1
United States|France|Germany|New Zealand|Spain 1
United States|France|Germany|Puerto Rico|United Kingdom 1
United States|France|Greece|Italy|Puerto Rico|Spain|United Kingdom 1
United States|Germany 1
United States|Germany|Netherlands|Poland|Puerto Rico|Slovakia 1
United States|Germany|Spain|United Kingdom 1
United States|India|Australia|Belgium|Brazil|Canada|Czech Republic|Egypt|France|Germany|Greece|Israel|Italy|Korea, Republic of|Pakistan|Poland|Puerto Rico|Romania|Russian Federation|Slovakia|Spain|Taiwan|Ukraine 1
United States|India|Korea, Republic of|Romania|Taiwan 1
United States|Japan|Korea, Republic of|Taiwan 1
United States|Korea, Republic of|Spain|Thailand|Turkey|United Kingdom 1
United States|New Zealand|Spain 1
United States|United Kingdom 1
Zambia 1

Sites per Study

Site_count Study_Count
1 738
2 81
3 54
4 49
5 28
6 24
7 28
8 30
9 18
10 21
11 22
12 17
13 7
14 13
15 18
16 15
17 8
18 16
19 15
20 12
21 15
22 9
23 9
24 12
25 12
26 7
27 5
28 11
29 2
30 1
31 3
32 9
33 2
34 4
35 5
36 2
37 5
38 7
39 5
40 1
41 3
42 6
43 6
44 3
45 3
46 1
48 5
49 3
51 2
52 1
53 3
54 1
55 3
56 1
60 1
61 1
62 2
63 3
66 3
67 4
68 2
71 3
73 3
74 1
75 1
76 1
77 1
80 1
81 1
82 1
86 1
87 3
91 1
93 2
97 1
98 1
100 1
101 1
102 1
104 1
106 1
107 1
109 1
112 1
113 1
114 1
116 2
119 1
123 1
124 1
132 1
142 1
144 1
147 1
171 1
184 1
187 1
191 1
210 1
227 1

Phase

Phase Study_Count
Phase 2 358
Phase 3 354
Phase 4 331
N/A 169
Phase 1 146
Phase 1/Phase 2 47
Phase 2/Phase 3 34
Early Phase 1 5

Number of Arms

Number_of_Arms Count_of_Studies
1 315
2 525
3 198
4 114
5 37
6 40
7 14
8 16
9 7
10 9
11 2
12 5
13 1
14 2
18 2
20 1
22 2
NA 154

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 22.0 2.000 4.00000 9.00000 2.0000 10.00 6.0000 5.000
1st Qu. 25.0 51.500 22.00000 30.00000 37.0000 66.50 100.0000 58.000
Median 26.0 136.000 36.50000 40.00000 75.0000 120.50 192.0000 136.500
Mean 35.4 1062.256 48.86301 61.33333 132.3654 219.50 353.4348 1568.512
3rd Qu. 52.0 309.750 60.00000 64.00000 154.0000 229.75 450.0000 307.750
Max. 52.0 50000.000 240.00000 548.00000 2000.0000 1224.00 5000.0000 221855.000

Trial Group Type

group_type Group_Count
Experimental 2428
Active Comparator 618
Placebo Comparator 211
NA 154
Other 94
No Intervention 87
Sham Comparator 4

Intervention Model

intervention_model Study_Count
Parallel Assignment 952
Single Group Assignment 417
NA 28
Crossover Assignment 18
Sequential Assignment 17
Factorial Assignment 12

Primary Purpose

primary_purpose Study_Count
Treatment 1085
Prevention 228
NA 26
Diagnostic 23
Health Services Research 20
Other 20
Basic Science 17
Screening 16
Supportive Care 8
Device Feasibility 1

Observational Studies

Studies by Country

Country Study_Count
United States 71
NA 65
China 38
France 22
Taiwan 15
Korea, Republic of 14
Spain 11
Australia 10
Japan 10
Germany 9
Netherlands 9
Canada 8
Egypt 8
Brazil 7
Hong Kong 7
India 6
United Kingdom 5
United States|Puerto Rico 5
Austria 4
Denmark 4
Italy 4
Mexico 4
Russian Federation 4
Switzerland 4
United States|Canada 4
Israel 3
Turkey 3
Zambia 3
Belgium 2
Bulgaria 2
Greece 2
Panama 2
Senegal 2
Singapore 2
Australia|France|Hong Kong|Italy|Korea, Republic of|New Zealand|Russian Federation|Singapore|Taiwan|Thailand 1
Australia|United States|Austria|Belgium|Canada|Czechia|Estonia|France|Germany|Italy|Netherlands|New Zealand|Poland|Puerto Rico|Spain|Sweden|United Kingdom 1
Austria|Bahrain|Bangladesh|Bosnia and Herzegovina|Bulgaria|China|Egypt|France|Germany|Hong Kong|India|Indonesia|Ireland|Jordan|Korea, Republic of|Lebanon|Macedonia, The Former Yugoslav Republic of|Morocco|New Zealand|Pakistan|Poland|Portugal|Romania|Saudi Arabia|Thailand|United Arab Emirates|United Kingdom 1
Austria|Bulgaria|China|France|Germany|Greece|Italy|Korea, Republic of|New Zealand|Poland|Portugal|Romania|Taiwan|Thailand|United Kingdom 1
Belgium|France|Germany|Netherlands|Switzerland|United Kingdom 1
China|United States|Argentina|Brazil|Canada|Colombia|Czechia|France|Germany|Greece|India|Italy|Korea, Republic of|Mexico|Philippines|Poland|Portugal|Romania|Russian Federation|Singapore|Spain|Taiwan|Thailand|Turkey 1
Colombia 1
Czech Republic 1
Ethiopia 1
France|Austria|Belgium|Greece|Israel|Italy|Poland|Portugal|Switzerland 1
France|Hungary|Austria|Brazil|Canada|Croatia|Macedonia, The Former Yugoslav Republic of|Mexico|Morocco|Poland|Romania|Serbia|Slovenia|Sweden 1
France|Italy 1
Gambia|Senegal 1
Georgia 1
Greece|Belgium|Egypt|Estonia|France|Germany|Hungary|Ireland|Italy|Kuwait|Lebanon|Macedonia, The Former Yugoslav Republic of|Morocco|Oman|Pakistan|Portugal|Qatar|Romania|Saudi Arabia|Serbia|Sweden|Switzerland|Syrian Arab Republic|Taiwan|Turkey|United Arab Emirates|United Kingdom 1
Hungary 1
Iceland 1
India|United States|Argentina|Brazil|China|France|Greece|Italy|Peru|Philippines|Poland|Romania|Russian Federation|Singapore|Spain|Taiwan|Thailand|United Kingdom 1
Italy|Belgium|Ireland|United Kingdom 1
Kenya 1
Korea, Republic of|Russian Federation 1
Lebanon|Albania|Algeria|Bahrain|Belgium|Bosnia and Herzegovina|Brazil|Egypt|Greece|Hungary|India|Iran, Islamic Republic of|Italy|Korea, Republic of|Kuwait|Macedonia, The Former Yugoslav Republic of|Morocco|Pakistan|Poland|Portugal|Qatar|Romania|Serbia|Slovakia|United Arab Emirates 1
Moldova, Republic of 1
Myanmar 1
Netherlands|United Kingdom 1
Poland 1
Puerto Rico 1
Serbia 1
Slovenia 1
Sweden 1
Thailand 1
Uganda 1
Ukraine 1
United States|Argentina|Australia|Austria|Belgium|Canada|Finland|France|Germany|Greece|Italy|Korea, Republic of|Mexico|Netherlands|New Zealand|Poland|Puerto Rico|Romania|Spain 1
United States|Argentina|Australia|Brazil|Canada|Denmark|France|Germany|Ireland|Italy|Japan|Korea, Republic of|Mexico|Poland|Puerto Rico|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Canada|Czechia|Estonia|France|Germany|Italy|Netherlands|New Zealand|Poland|Puerto Rico|Spain|Sweden|United Kingdom 1
United States|Australia|Bulgaria|Canada|Germany|Hungary|Italy|New Zealand|Romania|Turkey 1
United States|Canada|Germany|Puerto Rico 1
United States|Egypt 1
Uzbekistan 1

Sites per Study

Site_count Study_Count
1 284
2 19
3 11
4 9
5 4
6 5
7 4
8 3
9 5
10 3
11 4
12 2
14 1
16 1
17 1
18 2
19 2
21 2
22 1
25 1
26 2
27 2
28 1
30 1
33 1
34 1
37 2
39 1
43 1
45 2
46 1
53 1
57 1
58 1
59 1
61 1
66 1
70 1
73 1
74 1
75 1
84 1
86 1
88 1
90 1
101 1
104 1
106 1
125 1
156 1
161 1
170 1
249 1
261 1
266 1
272 1
290 1
323 1
325 1
388 1
402 1

Enrollment Metrics

Measure Observational
Min 1.000
1st Qu 88.000
Median 300.000
Mean 4137.075
3rd Qu 870.000
Max 815000.000

Observation Model

observational_model Study_Count
Cohort 258
Case-Only 42
NA 42
Other 22
Case-Control 19
Case Control 14
Ecologic or Community 8
Family-Based 2
Case-Crossover 1
Defined Population, Natural History 1

Time Perspective

time_perspective Study_Count
Prospective 280
Retrospective 58
Cross-Sectional 30
NA 22
Other 18
Longitudinal, Prospective 1

Registries

Studies by Country

Country Study_Count
China 7
NA 4
Korea, Republic of 2
Spain 2
United States 2
Austria|Belgium|Brazil|Georgia|Germany|Greece|Italy|Moldova, Republic of|Pakistan|Romania|Spain|Vietnam 1
Cameroon 1
Chile 1
Egypt 1
France 1
Germany 1
Italy 1
Japan 1
Portugal|Argentina|Austria|Belarus|Belgium|Bosnia and Herzegovina|Croatia|Czechia|Denmark|Estonia|Finland|France|Georgia|Germany|Greece|Hungary|Iceland|Ireland|Israel|Italy|Latvia|Lithuania|Luxembourg|Netherlands|Norway|Poland|Romania|Russian Federation|Serbia|Slovakia|Slovenia|Spain|Sweden|Switzerland|Ukraine|United Kingdom 1
Switzerland 1
United States|Australia|Belgium|Germany|Italy|New Zealand|Russian Federation|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|New Zealand|Puerto Rico|Spain|United Kingdom 1
United States|Canada 1
United States|Puerto Rico 1

Sites per Study

Site_count Study_Count
1 20
3 1
13 1
15 1
18 2
27 1
30 1
45 1
48 1
110 1
138 1

Enrollment Metrics

Measure Registries
Min 54.00
1st Qu 315.50
Median 500.00
Mean 8211.29
3rd Qu 1304.50
Max 200000.00

Registry Model

observational_model Study_Count
Cohort 24
Case-Control 3
Case-Crossover 1
Case-Only 1
Other 1
NA 1

Time Perspective

time_perspective Study_Count
Prospective 24
Cross-Sectional 3
Other 3
NA 1

Follow-up

target_duration Study_Count
5 Years 7
10 Years 4
1 Year 3
1 Day 2
24 Weeks 2
10 Months 1
144 Weeks 1
2 Weeks 1
2 Years 1
20 Years 1
3 Months 1
3 Years 1
30 Years 1
4 Years 1
48 Weeks 1
6 Months 1
62 Months 1
64 Weeks 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT04459897 Lyon Granulomatous Hepatitis Study https://ClinicalTrials.gov/show/NCT04459897 Recruiting Hospices Civils de Lyon 2023-01-01
NCT03396458 Hepatitis B Prevalence in the Turkish Population Living in Middle Limburg https://ClinicalTrials.gov/show/NCT03396458 Recruiting Hasselt University 2020-08-31
NCT03566563 Epidemiology of Chronic Hepatitis C and Disease Modelling https://ClinicalTrials.gov/show/NCT03566563 Recruiting Changi General Hospital 2019-02-18
NCT03366610 Study to Assess Clinical Outcomes in Chronic Hepatitis C Patients Previously Treated With Daclatasvir-Based Regimens https://ClinicalTrials.gov/show/NCT03366610 Completed Bristol-Myers Squibb 2019-04-30
NCT03825458 Creation of a Cohort for the Quantitation and Characterization of Circulating Viral RNAs as a New Biomarker of Hepatitis B Functional Cure. https://ClinicalTrials.gov/show/NCT03825458 Recruiting Hospices Civils de Lyon 2022-10-31
NCT03358108 A Prospective,Observational Follow-up Study of Nucleoside Treated Patients With Chronic Hepatitis B (OCEAN Study) https://ClinicalTrials.gov/show/NCT03358108 Recruiting Tongji Hospital 2020-12-01
NCT03341871 Glecaprevir/Pibrentasvir Drug Use Results Survey in Patients Infected With Hepatitis C Virus Genotype 1-6 https://ClinicalTrials.gov/show/NCT03341871 Active, not recruiting AbbVie 2020-12-31
NCT03329820 Quality of Life and Health Utility of Patients With CHB Infections https://ClinicalTrials.gov/show/NCT03329820 Completed The University of Hong Kong 2009-06-30
NCT03318887 Impact of Sofosbuvir and Daclatasvir Concentration on HCV RNA https://ClinicalTrials.gov/show/NCT03318887 Completed Hospices Civils de Lyon 2014-09-30
NCT03316313 Hepatitis C Screening in the Primary Care Setting https://ClinicalTrials.gov/show/NCT03316313 Completed New York Institute of Technology 2016-10-31
NCT03313154 Impact on QoL and Cognitive Functioning of New Antiviral Therapies in Subjects With Chronic Hepatitis HCV-related https://ClinicalTrials.gov/show/NCT03313154 Completed Azienda Ospedaliero Universitaria di Cagliari 2018-07-31
NCT03303599 Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6 https://ClinicalTrials.gov/show/NCT03303599 Completed AbbVie 2020-01-24
NCT03300414 Biologic Basis of Liver Cancer From Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03300414 Completed University of California, Davis 2018-12-14
NCT03290755 Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux https://ClinicalTrials.gov/show/NCT03290755 Completed University Hospital, Bordeaux 2018-03-13
NCT03254121 Genome Studies of Hepatocellular Carcinoma Developed in Hepatitis C Patients With Sustained Virological Response https://ClinicalTrials.gov/show/NCT03254121 Recruiting Karolinska Institutet 2021-01-01
NCT03248622 Hepatitis B Reactivation During Treatment With Direct-Acting Antiviral Agents for Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT03248622 Completed National Institutes of Health Clinical Center (CC) 2019-05-28
NCT03246048 Long Term Follow-up of Hepatitis C Cured Patients https://ClinicalTrials.gov/show/NCT03246048 Active, not recruiting Hospital Universitari Vall d’Hebron Research Institute 2021-01-31
NCT03245931 Hepatitis C Education for Pregnant Women With Opiate Addiction - Phase 1 https://ClinicalTrials.gov/show/NCT03245931 Completed TriHealth Inc. 2019-08-26
NCT03215732 Cross Sectional Survey on the Burden and Impacts of Chronic Hepatitis B in the Rural Area of Niakhar, Senegal https://ClinicalTrials.gov/show/NCT03215732 Completed French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2019-07-31
NCT03201718 A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs https://ClinicalTrials.gov/show/NCT03201718 Completed AbbVie 2019-10-11
NCT03200379 Nation-wide Hepatitis C Virus (HCV) Registry in Taiwan https://ClinicalTrials.gov/show/NCT03200379 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2037-06-15
NCT03200171 Effect of DAAs on Behavior of HCC in HCV Patients https://ClinicalTrials.gov/show/NCT03200171 Recruiting Al-Azhar University 2019-08-31
NCT03186235 T Regulatory Cells in Hepatitis c Infected Patients https://ClinicalTrials.gov/show/NCT03186235 Completed Assiut University 2019-08-01
NCT03181074 Early Post-marketing Study of Daclatasvir (Daklinza) in the Treatment of Chronic Hepatitis C (CHC) in Adults https://ClinicalTrials.gov/show/NCT03181074 Completed Bristol-Myers Squibb 2019-08-19
NCT03158818 Chronic Hepatitis B Virus Infection in Zambia https://ClinicalTrials.gov/show/NCT03158818 Recruiting University of Alabama at Birmingham 2021-01-31
NCT03149627 Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults https://ClinicalTrials.gov/show/NCT03149627 Completed University of Alabama at Birmingham 2018-12-19
NCT03149289 Hepatitis C Virus Infection in Patients With Hemoglobinopathies https://ClinicalTrials.gov/show/NCT03149289 Completed Società Italiana Talassemie ed Emoglobinopatie 2016-03-01
NCT03145844 Direct Acting Agents in Hepatitis C Patients https://ClinicalTrials.gov/show/NCT03145844 Completed Viral Hepatitis Society 2018-12-31
NCT03144440 Real World Experience of Chronic Hepatitis C (CHC) Treatment in Israel https://ClinicalTrials.gov/show/NCT03144440 Active, not recruiting Carmel Medical Center 2020-01-01
NCT03122132 Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks https://ClinicalTrials.gov/show/NCT03122132 Completed Hepa C 2018-01-01
NCT03109457 Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma https://ClinicalTrials.gov/show/NCT03109457 Completed Cairo University 2018-02-07
NCT03088995 Pilot Study of HIV and Hepatitis B and C Screening in Surgery https://ClinicalTrials.gov/show/NCT03088995 Completed Centre de Recherches et d’Etude sur la Pathologie Tropicale et le Sida 2017-09-01
NCT03088917 ‘Fibrosis in the Lost Hepatitis C Population - Track, Trace and Treat’ https://ClinicalTrials.gov/show/NCT03088917 Completed Radboud University 2019-12-01
NCT03042481 Off-therapy Response After Stopping Entecavir or Tenofovir https://ClinicalTrials.gov/show/NCT03042481 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2019-05-31
NCT03063723 Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs https://ClinicalTrials.gov/show/NCT03063723 Completed Third Affiliated Hospital, Sun Yat-Sen University 2016-12-01
NCT03038763 Vertical Transmission of Hepatitis C in Adult Children of Female Baby Boomers https://ClinicalTrials.gov/show/NCT03038763 Completed University of Pennsylvania 2019-06-30
NCT03053180 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation https://ClinicalTrials.gov/show/NCT03053180 Completed AbbVie 2017-12-18
NCT03000023 Anticipated and Perceived Benefits Following Hepatitis C Treatment https://ClinicalTrials.gov/show/NCT03000023 Completed University of North Carolina, Chapel Hill 2018-07-31
NCT02995252 The HOPE Study: Characterizing Patients With Hepatitis B and C https://ClinicalTrials.gov/show/NCT02995252 Recruiting University of Maryland, Baltimore 2020-01-31
NCT03002818 Quality of Life Measurement in Treatment Naïve Patients With Hepatitis C Virus (HCV) Genotype 1 (GT1) Suffering From Fatigue and Receiving Ombitasvir, Paritaprevir, and Ritonavir and Dasabuvir (Viekirax®/Exviera®) https://ClinicalTrials.gov/show/NCT03002818 Completed AbbVie 2018-04-25
NCT02994537 Study of the Clinical Features of Autoimmune Hepatitis https://ClinicalTrials.gov/show/NCT02994537 Recruiting West China Hospital 2019-10-02
NCT02985450 A Prospective Study of HBV Immunity and HBV Vaccination in Patients With NAFLD in Canada https://ClinicalTrials.gov/show/NCT02985450 Recruiting University of Calgary 2019-12-31
NCT02982993 Hepatitis C Infection in World Trade Center Responders https://ClinicalTrials.gov/show/NCT02982993 Completed Icahn School of Medicine at Mount Sinai 2018-07-12
NCT02196064 Hepatic Safety of Eviplera® in HIV/Hepatitis C (HCV)-Coinfected Patients Without HCV Treatment in the “The HEPAVIR HEPATIC SAFETY Cohort.” https://ClinicalTrials.gov/show/NCT02196064 Completed Andalusian Network for Design and Translation of Advanced Therapies 2015-07-31
NCT02945228 Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2 https://ClinicalTrials.gov/show/NCT02945228 Completed AbbVie 2019-07-26
NCT02909023 Performance of the HBV ELISPOT in the Detection of the T Cellular Immune Response in Patients Infected by HBV or Cured https://ClinicalTrials.gov/show/NCT02909023 Completed Hospices Civils de Lyon 2016-09-30
NCT02907996 Evaluate the Safety and Effectiveness of Sovaldi in Participants With Chronic Hepatitis C Virus (HCV) Infection in Korea https://ClinicalTrials.gov/show/NCT02907996 Recruiting Gilead Sciences 2021-09-30
NCT02881034 Ribavirin Bioavailability After Telaprevir Exposure https://ClinicalTrials.gov/show/NCT02881034 Completed Hospices Civils de Lyon 2015-02-28
NCT02877199 Anti-E1E2 Antibodies (D32.10 Epitope-binding Antibodies) and HCV Triple Therapy https://ClinicalTrials.gov/show/NCT02877199 Completed Hospices Civils de Lyon 2015-04-30
NCT02876419 A Long Term Follow-up Study of Patients From the REP 301 Protocol https://ClinicalTrials.gov/show/NCT02876419 Active, not recruiting Replicor Inc. 2019-11-13
NCT02863757 Follow-up of Chronic Hepatitis B Patients With Comorbid Nonalcoholic Fatty Liver Disease https://ClinicalTrials.gov/show/NCT02863757 Recruiting Humanity and Health Research Centre 2026-12-31
NCT02847507 Seroprevalence of Hepatitis E in HIV Positive Patients in Basque Country in 2016 (VIhVhEpb) https://ClinicalTrials.gov/show/NCT02847507 Completed Centre Hospitalier de la côte Basque 2018-01-31
NCT02851069 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Colombia https://ClinicalTrials.gov/show/NCT02851069 Completed AbbVie 2018-08-30
NCT02817594 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02817594 Completed AbbVie 2018-03-07
NCT02807402 Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Romania https://ClinicalTrials.gov/show/NCT02807402 Completed AbbVie 2017-08-04
NCT02799355 Treatment of Chronic Hepatitis With Sofosbuvir in Combination With Ribavirin With or Without Pegylated Interferon: North India Gastroenterology Consortium https://ClinicalTrials.gov/show/NCT02799355 Completed Dayanand Medical College and Hospital 2016-09-30
NCT02803138 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin and Patient Support Program in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02803138 Completed AbbVie 2018-10-21
NCT02798315 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study https://ClinicalTrials.gov/show/NCT02798315 Completed AbbVie 2017-06-12
NCT02796469 Meta-Analysis of Drug Therapy in Patients With Severe Alcoholic Hepatitis https://ClinicalTrials.gov/show/NCT02796469 Completed University Hospital, Lille 2016-05-31
NCT02791386 Rescue Treatment Pattern, Drug Resistance Recurrence, and Direct Medical Costs Associated With Chinese Patients With Chronic Hepatitis B and Drug Resistance to Nucleot(s)Ide Analogue Therapy https://ClinicalTrials.gov/show/NCT02791386 Completed Bristol-Myers Squibb 2017-10-30
NCT02785835 Hepatocellular Carcinoma in HIV-infected Patients https://ClinicalTrials.gov/show/NCT02785835 Recruiting Hospital Universitario de Valme 2016-12-31
NCT02773394 Study to Describe the Actual Situation of Hepatitis C Treatment in Brazil https://ClinicalTrials.gov/show/NCT02773394 Completed Janssen-Cilag Ltd. 2016-11-30
NCT02749864 Study to Evaluate the Prevalence of Hepatitis C in Spain in 2015 (PREVHEP) https://ClinicalTrials.gov/show/NCT02749864 Completed Instituto de Investigación Marqués de Valdecilla 2017-04-01
NCT02726022 A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels https://ClinicalTrials.gov/show/NCT02726022 Completed Hoffmann-La Roche 2011-07-31
NCT02725866 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Participants With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02725866 Completed AbbVie 2017-10-31
NCT02718573 Impact of Interferon-free Treatment for Hepatitis C Virus (HCV) on Blood Cells and Factors in Blood https://ClinicalTrials.gov/show/NCT02718573 Completed Icahn School of Medicine at Mount Sinai 2017-12-11
NCT02669940 Observational, Multi-Center Study of the Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in the Russian Federation https://ClinicalTrials.gov/show/NCT02669940 Completed AbbVie 2017-07-04
NCT02650024 Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes https://ClinicalTrials.gov/show/NCT02650024 Recruiting University of California, San Diego 2020-07-31
NCT02647879 Treatment as Prevention for Hepatitis C in Iceland https://ClinicalTrials.gov/show/NCT02647879 Recruiting Landspitali University Hospital 2020-12-31
NCT02640547 Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir, Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02640547 Completed AbbVie 2017-03-29
NCT02636608 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Hungary https://ClinicalTrials.gov/show/NCT02636608 Completed AbbVie 2018-05-23
NCT02629172 Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1 https://ClinicalTrials.gov/show/NCT02629172 Completed AbbVie 2019-02-28
NCT02618928 The Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in France https://ClinicalTrials.gov/show/NCT02618928 Completed AbbVie 2018-03-29
NCT02615145 Real World Evidence of the Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Germany (LIFE-C) https://ClinicalTrials.gov/show/NCT02615145 Completed AbbVie 2018-03-26
NCT02597790 A Prospective, Longitudinal Study of Endothelial Function in HIV/HCV Coinfected Subjects https://ClinicalTrials.gov/show/NCT02597790 Completed University of California, Los Angeles 2019-01-31
NCT02597270 An Observational/Non-interventional, Study of NS3/4a Protease and NS5A Protein of Hepatitis C Virus in Brazilian Participants With Chronic HCV Infection https://ClinicalTrials.gov/show/NCT02597270 Completed Janssen-Cilag Ltd. 2016-11-30
NCT02591277 Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02591277 Completed Gilead Sciences 2017-11-01
NCT02592057 Safety and Efficacy of Sofosbuvir-based Regimens in Clinical Practice for the Treatment of Chronic Hepatitis C Virus Infection in India https://ClinicalTrials.gov/show/NCT02592057 Completed Gilead Sciences 2017-11-30
NCT02582671 The Effectiveness of ABT-450/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland https://ClinicalTrials.gov/show/NCT02582671 Completed AbbVie 2017-11-29
NCT02582658 Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Austria (REAL) https://ClinicalTrials.gov/show/NCT02582658 Completed AbbVie 2017-01-12
NCT02581189 Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada https://ClinicalTrials.gov/show/NCT02581189 Completed AbbVie 2017-12-20
NCT04356404 Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients https://ClinicalTrials.gov/show/NCT04356404 Recruiting Chinese University of Hong Kong 2022-05-31
NCT00050115 Collection of Biological Samples From Patients With Hepatitis-Associated Aplastic Anemia https://ClinicalTrials.gov/show/NCT00050115 Completed National Institutes of Health Clinical Center (CC) NA
NCT00004850 Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT00004850 Active, not recruiting National Institutes of Health Clinical Center (CC) NA
NCT01350648 Long-Term Study of Liver Disease in People With Hepatitis B and/or Hepatitis C With or Without HIV Infection https://ClinicalTrials.gov/show/NCT01350648 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02566148 Life Course, HIV and Hepatitis B Among African Migrants Living in Ile-de-France https://ClinicalTrials.gov/show/NCT02566148 Completed French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2012-02-29
NCT01263600 Hepatitis B Research Network Pediatric Cohort Study (HBRN) https://ClinicalTrials.gov/show/NCT01263600 Active, not recruiting University of Pittsburgh 2020-09-30
NCT01263587 Hepatitis B Research Network Adult Cohort Study https://ClinicalTrials.gov/show/NCT01263587 Active, not recruiting University of Pittsburgh 2020-09-30
NCT02562742 Use-Results Surveillance Study of Sovaldi® Plus Rebetol® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02562742 Completed Gilead Sciences 2017-06-12
NCT02557646 An Observational Study to Assess the Effect of Cumulative Ribavirin Dose in Participants With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02557646 Completed Hoffmann-La Roche 2014-03-31
NCT02556307 A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients https://ClinicalTrials.gov/show/NCT02556307 Completed Hoffmann-La Roche 2014-07-31
NCT02548325 Prevalence of Hepatitis B in Vallés Occidental. Observational Multicentric Study https://ClinicalTrials.gov/show/NCT02548325 Completed Corporacion Parc Tauli 2015-05-31
NCT02545400 Quantification of Side Effects During Hepatitis C Therapy https://ClinicalTrials.gov/show/NCT02545400 Completed Medical University of Graz 2014-06-30
NCT02537379 Use-Results Surveillance Study of Sovaldi® Plus Copegus® in Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT02537379 Completed Gilead Sciences 2017-06-05
NCT02545335 Neutrophil Function During Therapy With Protease Inhibitors in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02545335 Active, not recruiting Medical University of Graz 2020-12-31
NCT02533544 Treatment Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in naïve Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02533544 Completed The Catholic University of Korea 2018-10-31
NCT02531269 Effectiveness Of Daclatasvir-Based Regimens In Patients With Chronic Hepatitis C Infection In Europe: Experience From Named Patient Program And From Early Post-Marketing Authorization Period https://ClinicalTrials.gov/show/NCT02531269 Completed Bristol-Myers Squibb 2016-02-29
NCT02526641 Macrophages, Portal Hypertension, and Liver Function During AbbVie Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02526641 Active, not recruiting University of Aarhus 2019-03-31
NCT02528461 Macrophage Activation Markers During Sofosbuvir-based Treatment Regimes of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02528461 Completed University of Aarhus 2019-01-31
NCT02511743 Knowledge and Practice of Chinese Medical Specialists Regarding Chronic Hepatitis B Virus Infection https://ClinicalTrials.gov/show/NCT02511743 Completed Peking University First Hospital 2015-11-30
NCT02508090 Long-Term Extension Study of Miravirsen Among Participants With Genotype 1 Chronic Hepatitis C (CHC) Who Have Not Responded to Pegylated-Interferon Alpha Plus Ribavirin https://ClinicalTrials.gov/show/NCT02508090 Completed Hoffmann-La Roche 2017-01-13
NCT02505243 Evaluation of RIBAvirin Plasma COncentrations in Patients With Chronic Hepatitis C Infection Routinely Treated With Modern DAA Regimens https://ClinicalTrials.gov/show/NCT02505243 Completed Radboud University 2016-06-30
NCT02387463 Efficacy of Extended Peginterferon Alpha 2a Treatment in HBeAg Positive Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT02387463 Completed Beijing Ditan Hospital 2017-05-21
NCT02368522 Comparative Assessment of Utilization of Antiviral Therapies in Hepatitis C and Effectiveness of Daclatasvir-containing Regimens in Real-life Clinical Care in Europe (CMPASS-EU) https://ClinicalTrials.gov/show/NCT02368522 Completed Bristol-Myers Squibb 2017-02-28
NCT02366286 Hepatitis B and Hepatitis C as Risk Factors for Hepatocellular Carcinoma in African and Asian Immigrants https://ClinicalTrials.gov/show/NCT02366286 Active, not recruiting Mayo Clinic 2022-12-31
NCT02344498 Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa https://ClinicalTrials.gov/show/NCT02344498 Active, not recruiting Oslo University Hospital 2020-12-31
NCT02344680 Liver Fibrosis in Zambian HIV-HBV Co-infected Patients https://ClinicalTrials.gov/show/NCT02344680 Active, not recruiting University of Alabama at Birmingham 2024-08-31
NCT02324218 This Study Aims to Determine the Incidence, of Hepatitis B Diagnosis Among Diabetes Mellitus Patients of 0-80 Years of Age https://ClinicalTrials.gov/show/NCT02324218 Completed GlaxoSmithKline 2015-01-31
NCT02323308 Isolated Anti-HBc Serological Profile in HIV Infected Patients: Immunological, Virological Characteristics and Response to Hepatitis B Vaccination https://ClinicalTrials.gov/show/NCT02323308 Completed French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2014-06-30
NCT02275221 Immune Response in Patients With Hepatitis B and C Infection https://ClinicalTrials.gov/show/NCT02275221 Recruiting Basildon and Thurrock University Hospitals NHS Foundation Trust 2019-12-31
NCT02275195 Immune Cell Dysfunction in Severe Alcoholic Hepatitis https://ClinicalTrials.gov/show/NCT02275195 Recruiting Basildon and Thurrock University Hospitals NHS Foundation Trust 2019-12-31
NCT02267473 Hepatitis B Patients Under Oral Nucleos(t)Ide Treatment With Intermittent Assessment of Kidney Function https://ClinicalTrials.gov/show/NCT02267473 Active, not recruiting Johann Wolfgang Goethe University Hospital 2020-10-31
NCT02201407 An Observational Study in Participants With Chronic Hepatitis B (CHB) Receiving Therapy With Peginterferon Alfa-2a 40 Kilodaltons (kD) (PEGASYS) - The PRO B Study https://ClinicalTrials.gov/show/NCT02201407 Completed Hoffmann-La Roche 2017-04-10
NCT02190253 Seroprevalence of Hepatitis E in People With an Organ Transplant https://ClinicalTrials.gov/show/NCT02190253 Completed National Institutes of Health Clinical Center (CC) 2019-02-05
NCT02172898 Alcoholic Hepatitis: A Multicenter, Observational Study by the TREAT Consortium https://ClinicalTrials.gov/show/NCT02172898 Completed Indiana University 2018-06-29
NCT02167113 Collection of Samples for the Clinical Evaluation of the Aptima HBV (Hepatitis B Virus) Quant (Quantification) Assay https://ClinicalTrials.gov/show/NCT02167113 Completed Hologic, Inc. 2016-02-29
NCT02129829 PROLIFICA - West African Treatment Cohort for Hepatitis B https://ClinicalTrials.gov/show/NCT02129829 Active, not recruiting Imperial College London 2020-04-01
NCT02125071 Study on the Pharmacokinetic Characteristics of I.V. Hepabig Injection Used for Prevention of Hepatitis B Relapse After Liver Transplantation https://ClinicalTrials.gov/show/NCT02125071 Completed Seoul St. Mary’s Hospital 2015-08-31
NCT02112890 Study to Assess Seroprevalence of Hepatitis A, Hepatitis B and Bordetella Pertussis in Mexico https://ClinicalTrials.gov/show/NCT02112890 Completed GlaxoSmithKline 2016-05-02
NCT02108444 Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma Patients https://ClinicalTrials.gov/show/NCT02108444 Completed Peking University 2013-12-31
NCT02106156 Observational Study Evaluating the Quality of Pegylated Interferon Alfa-2a and Ribavirin Treatment for Chronic Hepatitis C in Cooperation With the BNG (Association of German Resident Gastroenterologists) https://ClinicalTrials.gov/show/NCT02106156 Completed Hoffmann-La Roche 2013-09-30
NCT02103699 A Study to Examine Patient Characteristics, Health Care Management and Health Outcomes of Hepatitis C Virus (HCV) Patients Treated With Simeprevir https://ClinicalTrials.gov/show/NCT02103699 Completed Janssen Scientific Affairs, LLC 2015-11-30
NCT02102451 Control and Elimination Within Australia of Hepatitis C From People Living With HIV https://ClinicalTrials.gov/show/NCT02102451 Active, not recruiting Kirby Institute 2020-12-31
NCT02075918 Integrated Approaches for Identifying Molecular Targets in Alcoholic Hepatitis https://ClinicalTrials.gov/show/NCT02075918 Completed University of Pittsburgh 2019-05-31
NCT02075294 Efficacy and Safety Study of Adefovir and Entecavir for Elderly With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02075294 Completed Beijing 302 Hospital 2012-10-31
NCT02069678 Serum Hepatitis B Surface Antigen Levels to Guide the Stopping of Entecavir in HBeAg-negative Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02069678 Completed Chinese University of Hong Kong 2013-09-30
NCT02068963 Collection of Plasma and Serum Samples From Individuals Initiating Sofosbuvir for Chronic Hepatitis C for Testing https://ClinicalTrials.gov/show/NCT02068963 Completed Hologic, Inc. 2015-04-30
NCT02065999 Surveillance for Antiviral Resistant Variants in Chronic Hepatitis C Patients https://ClinicalTrials.gov/show/NCT02065999 Recruiting Kirby Institute 2022-04-30
NCT01311947 Hepatitis B Virus Mutants and the Therapeutic Effect of Peginterferon Alfa-2a in HBeAg-Positive Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01311947 Completed China Medical University Hospital 2012-03-31
NCT01298037 HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01298037 Active, not recruiting University of Pennsylvania 2021-05-31
NCT01293279 HCV (Hepatitis C Virus) Viral and Host Genotyping (IL28B, Interleukin 28B) in China https://ClinicalTrials.gov/show/NCT01293279 Completed Peking University People’s Hospital 2011-06-30
NCT01296529 Study on Immunopathogenesis in HIV and Hepatitis C Coinfection https://ClinicalTrials.gov/show/NCT01296529 Completed Rush University Medical Center 2011-12-31
NCT01283074 An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HbeAg-negative Chronic Hepatitis B (Perseas) https://ClinicalTrials.gov/show/NCT01283074 Completed Hoffmann-La Roche 2012-11-30
NCT01280656 A Retrospective Study to Assess the Impact of the Use of Interferon in Patients With Chronic Hepatitis C (DECISION) https://ClinicalTrials.gov/show/NCT01280656 Completed Hoffmann-La Roche 2012-11-30
NCT01272479 Prohepcidin, Inflammation and Iron Homeostasis in Hemodialysis Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01272479 Completed Istanbul University 2010-03-31
NCT02057003 Real-life Security and Efficacy of DAA-based Therapy in HCV/HIV-Coinfected Patients https://ClinicalTrials.gov/show/NCT02057003 Recruiting Valme University Hospital 2020-12-31
NCT02056054 De Novo Autoimmune Hepatitis in Pediatric Liver Transplantation https://ClinicalTrials.gov/show/NCT02056054 Recruiting Yale University 2020-05-31
NCT02044055 Mother-to-child Hepatitis D Transmission https://ClinicalTrials.gov/show/NCT02044055 Completed Hopital Lariboisière 2017-04-30
NCT02044523 Noninvasive Staging of Liver Fibrosis: MR vs Ultrasound https://ClinicalTrials.gov/show/NCT02044523 Completed Centre hospitalier de l’Université de Montréal (CHUM) 2018-06-30
NCT04202081 Voices From the Black Community: Hepatitis C Research Participation https://ClinicalTrials.gov/show/NCT04202081 Completed University of North Carolina, Chapel Hill 2020-05-15
NCT02951364 Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea https://ClinicalTrials.gov/show/NCT02951364 Recruiting Gilead Sciences 2021-10-31
NCT02011932 Prospective Observational Study of Disease Progression in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02011932 Active, not recruiting Beijing YouAn Hospital 2011-06-30
NCT02006823 Patient Self-management and Gene Guided Therapy for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02006823 Completed Duke University 2014-07-31
NCT02002065 The Fifth-year Follow-up Study for the Phase IV Clinical Trial of Hepatitis A Vaccine in Healthy Children https://ClinicalTrials.gov/show/NCT02002065 Completed Sinovac Biotech Co., Ltd 2013-11-30
NCT02000063 Australian Trial in Acute Hepatitis C Recall Study https://ClinicalTrials.gov/show/NCT02000063 Completed Kirby Institute 2014-03-31
NCT01988753 Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases https://ClinicalTrials.gov/show/NCT01988753 Completed Baylor College of Medicine 2016-06-30
NCT01980290 Telaprevir With Peginterferon Alfa & Ribavirin in Ex-People Who INject Drugs Infected by Genotype 1 Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01980290 Completed Janssen Pharmaceutica N.V., Belgium 2015-02-28
NCT01970254 Widespread vs. Selective Screening for Hepatitis B Infection Prior to Chemotherapy https://ClinicalTrials.gov/show/NCT01970254 Active, not recruiting M.D. Anderson Cancer Center 2020-12-31
NCT01958229 Efficacy Study of Telbivudine in Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT01958229 Completed National Taiwan University Hospital 2012-03-31
NCT01953458 Therapeutic Option for Hepatitis B and C: a French Cohort https://ClinicalTrials.gov/show/NCT01953458 Recruiting French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2022-08-31
NCT01957618 The Follow-up Study of Chronic Hepatitis B Patients With Liver Cirrhosis Receiving Anti-HBV Therapy https://ClinicalTrials.gov/show/NCT01957618 Enrolling by invitation National Taiwan University Hospital 2012-01-31
NCT01918462 Protective Immune Mechanisms in Alcoholic Hepatitis https://ClinicalTrials.gov/show/NCT01918462 Recruiting University of Aarhus 2018-04-30
NCT01921400 The Pathogenesis of Hepatitis C Virus Vertical Transmission https://ClinicalTrials.gov/show/NCT01921400 Completed University of North Carolina, Chapel Hill 2017-12-31
NCT01855997 A Study to Collect Blood Biomarker Samples From Participants With Chronic Hepatitis B (CHB) Who Received Treatment With Pegasys (Peginterferon Alfa-2a) ± Nucleoside/Nucleotide Analogue https://ClinicalTrials.gov/show/NCT01855997 Completed Hoffmann-La Roche 2014-11-28
NCT01850745 Multidisciplinary Support Program in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01850745 Completed Parc de Salut Mar 2009-01-31
NCT01838070 Regulatory Post-Marketing Surveillance Study for Hepatitis A Vaccine (AVAXIM 160U) https://ClinicalTrials.gov/show/NCT01838070 Completed Sanofi 2015-11-30
NCT01826760 Study of the Model to Predict 3-month Mortality Risk of Acute-on-chronic Hepatitis B Liver Failure https://ClinicalTrials.gov/show/NCT01826760 Completed Wenzhou Medical University 2010-05-31
NCT01810835 Prevention of Hepatitis B Virus Mother-to-child Transmission by Serovaccination. https://ClinicalTrials.gov/show/NCT01810835 Completed Hopital Lariboisière 2013-11-30
NCT01796457 HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01796457 Active, not recruiting University of Pennsylvania 2020-07-31
NCT03579576 Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar https://ClinicalTrials.gov/show/NCT03579576 Completed Right to Care 2019-03-30
NCT01782794 Acceptability of Hepatitis B Vaccination in General Population https://ClinicalTrials.gov/show/NCT01782794 Completed GlaxoSmithKline 2012-06-30
NCT01777074 Acceptability of Hepatitis B Vaccination in General Practitioners and Paediatricians https://ClinicalTrials.gov/show/NCT01777074 Completed GlaxoSmithKline 2012-04-30
NCT01772121 Observational Study on Prevalence of Host and Viral Genotypes in Chronic Hepatitis B and Hepatitis C Patients in India https://ClinicalTrials.gov/show/NCT01772121 Completed Gilead Sciences 2012-10-31
NCT01771653 Comparison of Two Triple Regimens for Treatment and Retreatment of Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT01771653 Completed Southern Illinois University 2015-07-31
NCT01766895 Long-term Follow Up of Viral Hepatitis in Uremic Patients in Taiwan https://ClinicalTrials.gov/show/NCT01766895 Recruiting Kaohsiung Medical University Chung-Ho Memorial Hospital 2021-01-31
NCT01750216 An Observational Study of Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) on Predictive Values of RVR on Sustained Virological Response in Different Stages of Liver Fibrosis in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 https://ClinicalTrials.gov/show/NCT01750216 Completed Hoffmann-La Roche 2015-01-31
NCT01732354 Study for Consolidation Period of Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01732354 Completed Tainan Municipal Hospital 2013-11-20
NCT01732081 “Real-life” Cohort of Patients With Chronic Hepatitis B Virus Infection https://ClinicalTrials.gov/show/NCT01732081 Recruiting University Hospital, Strasbourg, France 2021-01-31
NCT01730508 An Observational Study of Pegasys (Peginterferon Alfa-2a) in Chinese Patients With HBeAg Negative Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01730508 Completed Hoffmann-La Roche 2017-06-25
NCT03350074 HBV Envelope Proteins Variability on HBs Antigen Clearance Under Nucleos(t)Ide Analogue Therapy https://ClinicalTrials.gov/show/NCT03350074 Completed Central Hospital, Nancy, France 2016-05-01
NCT01726400 In Hepatitis C Patients Treated With Interferon and Ribavirin, Does Hepcidin Contribute to Treatment Induced Anaemia https://ClinicalTrials.gov/show/NCT01726400 Completed Fremantle Hospital and Health Service 2014-01-31
NCT01711164 The Role of FGL2-FcgammaRIIB Inhibitory Pathway in Human Viral Hepatitis https://ClinicalTrials.gov/show/NCT01711164 Completed University Health Network, Toronto 2016-05-31
NCT01705717 A Retrospective Study of Real World Treatment Outcomes of Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01705717 Completed Hoffmann-La Roche 2012-05-01
NCT01705704 A Retrospective Biomarker Study of Stored Samples Obtained From Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01705704 Completed Hoffmann-La Roche 2013-02-28
NCT01679834 An Observational Study of Pegasys in Dual- or Triple-Therapy in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01679834 Completed Hoffmann-La Roche 2017-07-14
NCT01671046 An Observational Study To Assess Liver Fibrosis Stages in Patients With Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT01671046 Completed Hoffmann-La Roche 2015-12-31
NCT01667081 Durability of Virologic Response and/or Viral Resistance Patterns in Participants With Chronic Hepatitis C Who Have Been Previously Treated With Grazoprevir (MK-5172) (MK-5172-017) https://ClinicalTrials.gov/show/NCT01667081 Enrolling by invitation Merck Sharp & Dohme Corp. 2021-05-24
NCT01667432 An Observational Study of Peginterferon Alfa-2a (PEGASYS®) in Patients With HBeAg Positive or HBeAg Negative Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01667432 Completed Hoffmann-La Roche 2014-08-12
NCT01659567 A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C https://ClinicalTrials.gov/show/NCT01659567 Completed Hoffmann-La Roche 2015-10-20
NCT01645969 A Follow-Up Study of Patients With HBeAg Positive Chronic Hepatitis B Treated With Pegasys (Peginterferon Alfa-2a) in Study ML22265 https://ClinicalTrials.gov/show/NCT01645969 Completed Hoffmann-La Roche 2012-10-31
NCT01634919 Histologic Changes and Noninvasive Assessment in Hepatitis C Patients Treated With Peginterferon Alpha-2a and Ribavirin https://ClinicalTrials.gov/show/NCT01634919 Completed Seoul National University Boramae Hospital 2017-02-17
NCT01623778 Optimization of Antiviral Therapy of Chronic HBV Infection https://ClinicalTrials.gov/show/NCT01623778 Completed Changhai Hospital 2011-12-31
NCT01609049 An Observational Study of Peginterferon Alfa-2a in Combination With Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis https://ClinicalTrials.gov/show/NCT01609049 Completed Hoffmann-La Roche 2015-06-22
NCT01604291 An Observational Study of Dual and Triple Therapies Based on Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01604291 Completed Hoffmann-La Roche 2016-02-10
NCT01577069 Predictive Factors of the Treatment Failure in Hepatitis C Virus (HCV) Infected Patients Treated With Telaprevir https://ClinicalTrials.gov/show/NCT01577069 Completed Association HGE CHU Bordeaux Sud 2013-01-31
NCT01574521 Seroepidemiologic Study of Spermatozoal Transmission of Hepatitis B Virus (HBV) https://ClinicalTrials.gov/show/NCT01574521 Completed Taizhou Hospital 2010-12-31
NCT01534728 Identification of Hepatitis C Virus (HCV) Specific T Cells https://ClinicalTrials.gov/show/NCT01534728 Completed Institut National de la Santé Et de la Recherche Médicale, France 2014-03-31
NCT01544582 Drug Utilization of Boceprevir and Clinical Management of Health Outcomes of Interest in Chronic Hepatitis C Participants (P08518) https://ClinicalTrials.gov/show/NCT01544582 Completed Merck Sharp & Dohme Corp. 2015-07-31
NCT01531166 A Cohort Study in Korean Patients With Chronic Hepatitis B (CHB) Receiving Pegylated Interferon https://ClinicalTrials.gov/show/NCT01531166 Completed Yonsei University 2014-08-31
NCT01525810 Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial https://ClinicalTrials.gov/show/NCT01525810 Completed Bristol-Myers Squibb 2014-11-30
NCT01508130 An Observational Study of Peginterferon (e.g. Pegasys)-Based Direct Acting Antiviral Triple Therapy in Patients With Chronic Hepatitis C Genotype 1 https://ClinicalTrials.gov/show/NCT01508130 Completed Hoffmann-La Roche 2014-03-31
NCT01502397 Risk of Hepatitis B Reactivation in Patients With Prior HBV Exposure Undergoing Rituximab-containing Chemotherapy: A Prospective Study https://ClinicalTrials.gov/show/NCT01502397 Completed The University of Hong Kong 2015-12-31
NCT01500265 Assessment and Monitoring of Renal Proximal Tubular Tolerance of Nucleoside and Nucleotide Analogues Using Early Screening Tools in Patients Chronically Mono-infected With Hepatitis B Virus https://ClinicalTrials.gov/show/NCT01500265 Completed University Hospital, Limoges 2013-12-31
NCT01492504 Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial https://ClinicalTrials.gov/show/NCT01492504 Completed Bristol-Myers Squibb 2018-03-16
NCT01481649 Risk of Hepatitis B Reactivation After Bone Marrow Transplantation With Prior Hepatitis B Virus (HBV) Exposure https://ClinicalTrials.gov/show/NCT01481649 Completed The University of Hong Kong 2015-02-28
NCT01476995 Prognostic Indicators as Provided by the EPIC ClearView https://ClinicalTrials.gov/show/NCT01476995 Completed Epic Research & Diagnostics, Inc. 2011-06-30
NCT01474811 HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network https://ClinicalTrials.gov/show/NCT01474811 Recruiting University of North Carolina, Chapel Hill 2020-12-31
NCT01464008 The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01464008 Completed Beijing Ditan Hospital 2011-05-31
NCT01457768 A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response https://ClinicalTrials.gov/show/NCT01457768 Completed Gilead Sciences 2018-04-09
NCT01457755 Gilead Sustained Virologic Response (SVR) Registry https://ClinicalTrials.gov/show/NCT01457755 Completed Gilead Sciences 2017-03-28
NCT01453244 Pharmacogenomic Research in Korean Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT01453244 Completed Inje University 2013-03-31
NCT01448915 Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs) https://ClinicalTrials.gov/show/NCT01448915 Active, not recruiting Johns Hopkins University 2021-04-30
NCT01447680 Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing https://ClinicalTrials.gov/show/NCT01447680 Completed G & W Laboratories Inc. 2012-12-31
NCT01447446 An Observational Study on Dual And Triple Therapies Based on Peginterferon Alfa (e.g. Pegasys) in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01447446 Completed Hoffmann-La Roche 2015-07-31
NCT01429155 Outcomes in Hepatitis C After Living Donor Liver Transplantation in Association With Interleukin 28 B https://ClinicalTrials.gov/show/NCT01429155 Completed Henry Ford Health System 2013-01-31
NCT01413490 Hepatitis C Rimantadine and Antiviral Combination Therapy https://ClinicalTrials.gov/show/NCT01413490 Completed The Leeds Teaching Hospitals NHS Trust 2015-03-31
NCT01402583 Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT01402583 Completed University of Modena and Reggio Emilia 2011-08-31
NCT01401400 Genetic Study of Peginterferon Treatment in Hepatitis B Patients: The GIANT-B Study https://ClinicalTrials.gov/show/NCT01401400 Completed Foundation for Liver Research 2015-06-30
NCT01405183 Association Between Hepatitis C Infection and Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01405183 Completed Henry Ford Health System 2013-08-31
NCT01392742 An Observational Study on Predictive Factors of Response in Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Ribavirin https://ClinicalTrials.gov/show/NCT01392742 Completed Hoffmann-La Roche 2014-07-31
NCT01356901 Persistence, Adherence and Clinical Effectiveness of Entecavir in Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT01356901 Completed Bristol-Myers Squibb 2015-01-31
NCT01353989 Hepatitis A Vaccination in the Elderly https://ClinicalTrials.gov/show/NCT01353989 Completed Rijnstate Hospital 2015-07-31
NCT01344889 An Observational Study on The Prediction of Adverse Events in Patients With Chronic Hepatitis C Receiving a Long-Acting Interferon Plus Ribavirin (GUARD-C) https://ClinicalTrials.gov/show/NCT01344889 Completed Hoffmann-La Roche 2013-06-30
NCT01323452 Entecavir for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01323452 Completed Foundation for Liver Research 2011-01-31
NCT04389268 P300 in Early Cognitive Impairment in Hepatitis C Virus https://ClinicalTrials.gov/show/NCT04389268 Completed Mansoura University Hospital 2019-01-01
NCT04371276 Seroepidemiology of Viral Hepatitis in Hong Kong https://ClinicalTrials.gov/show/NCT04371276 Enrolling by invitation Chinese University of Hong Kong 2020-07-31
NCT04330508 Effects of Direct-acting Antiviral Agents on HCV Cognitive Function, and Depression in HCV Related Cirrhosis: A Prospective Clinical Trial https://ClinicalTrials.gov/show/NCT04330508 Recruiting Postgraduate Institute of Medical Education and Research 2020-10-31
NCT04352309 Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis https://ClinicalTrials.gov/show/NCT04352309 Recruiting AbbVie 2021-04-20
NCT04310787 Long-term Prognosis of Patients With Hepatitis B Related Acute-on-chronic Liver Failure https://ClinicalTrials.gov/show/NCT04310787 Recruiting Third Affiliated Hospital, Sun Yat-Sen University 2020-08-15
NCT04264312 Baseline Investigation of Chronic Hepatitis B Viruses Infections: Who is Eligible for Treated Criteria https://ClinicalTrials.gov/show/NCT04264312 Completed Centers for Disease Control and Prevention, China 2019-09-28
NCT04247490 Autoimmune Hepatitis in Pediatric Patients https://ClinicalTrials.gov/show/NCT04247490 Completed University Hospital of Ferrara 2019-12-31
NCT04234139 Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation https://ClinicalTrials.gov/show/NCT04234139 Enrolling by invitation Johns Hopkins University 2025-12-31
NCT04214028 A Study of the Safety, Effectiveness and Clinical Use of Maviret in Adolescent Patients With Chronic Hepatitis C Virus https://ClinicalTrials.gov/show/NCT04214028 Recruiting AbbVie 2024-12-30
NCT04211805 Maternal Therapy With TAF Versus TDF to Prevent Vertical Transmission of Hepatitis B https://ClinicalTrials.gov/show/NCT04211805 Recruiting New Discovery LLC 2021-09-30
NCT04208035 Hepatitis C Elimination in the Netherlands https://ClinicalTrials.gov/show/NCT04208035 Recruiting Radboud University 2021-01-01
NCT04189627 A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation https://ClinicalTrials.gov/show/NCT04189627 Recruiting AbbVie 2021-03-01
NCT04170452 Study the Content of the HBV DNA in Liver Biopsy in the Patients Chronic Hepatitis Delta https://ClinicalTrials.gov/show/NCT04170452 Enrolling by invitation Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan 2020-06-01
NCT04160897 Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis https://ClinicalTrials.gov/show/NCT04160897 Enrolling by invitation Ruijin Hospital 2020-10-31
NCT02786758 Eliminating Hepatitis C Transmission by Enhancing Care and Treatment Among HIV Co-infected Individuals https://ClinicalTrials.gov/show/NCT02786758 Completed Macfarlane Burnet Institute for Medical Research and Public Health Ltd 2019-07-31
NCT04135235 Effect and Safety of Propofol Fumarate for Mother-to-child Blocking of Hepatitis B https://ClinicalTrials.gov/show/NCT04135235 Recruiting Beijing Ditan Hospital 2021-08-01
NCT04103840 Invasive Fungal Infections in Severe Alcohol-associated Hepatitis https://ClinicalTrials.gov/show/NCT04103840 Recruiting Postgraduate Institute of Medical Education and Research 2022-10-01
NCT04090164 Association of Hepatitis C Virus With Breast Cancer https://ClinicalTrials.gov/show/NCT04090164 Active, not recruiting Mansoura University 2020-06-30
NCT04094272 Pulmonary Arterial Hypertension in Patients With Direct-Acting Antiviral Medications for Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT04094272 Completed Kantonsspital Olten 2019-05-01
NCT04071353 Observational Cohort Study of Clinical Outcomes After Antiviral Therapy for Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT04071353 Recruiting Beijing Ditan Hospital 2020-08-01
NCT04057001 Hepatitis C Positive Organ to Recipient Hepatitis C Negative Longitudinal Transplant Study https://ClinicalTrials.gov/show/NCT04057001 Recruiting Yale University 2020-06-30
NCT04047680 eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs https://ClinicalTrials.gov/show/NCT04047680 Completed National Taiwan University Hospital 2018-12-31
NCT04038320 Simplified Antiviral Treatment Strategy for Hepatitis C in Ukraine https://ClinicalTrials.gov/show/NCT04038320 Completed Right to Care 2019-03-30
NCT04028856 Cohort Study of Efficacy and Safety of Interferon Intermittent Treatment of Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT04028856 Completed Beijing Ditan Hospital 2019-06-30
NCT03993925 Enhancing Access to Care for Chronic Hepatitis C Infected Populations in Hong Kong https://ClinicalTrials.gov/show/NCT03993925 Recruiting The University of Hong Kong 2020-09-30
NCT03980301 Screening Hepatitis Positive Women for Congenital Anomalies https://ClinicalTrials.gov/show/NCT03980301 Recruiting Aljazeera Hospital 2020-06-15
NCT03979053 Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis. https://ClinicalTrials.gov/show/NCT03979053 Completed Perspectum Diagnostics Ltd 2019-10-31
NCT03977857 Computed Tomography Liver Volume for Predicting Short-term Mortality in Hepatitis B‐Acute‐on‐Chronic Liver Failure https://ClinicalTrials.gov/show/NCT03977857 Completed First Affiliated Hospital Xi’an Jiaotong University 2019-12-31
NCT03977987 Maternal Antiviral Treatment and Infants Immunoprophylaxis in the Prevention of Mother-to-child Transmission https://ClinicalTrials.gov/show/NCT03977987 Completed Huashan Hospital 2018-12-30
NCT03908294 Change of Glucose Metabolism and Fibrosis Markers in Patients With Hepatitis C Under Treatment With Antiviral Agents https://ClinicalTrials.gov/show/NCT03908294 Completed Johann Wolfgang Goethe University Hospital 2020-01-01
NCT03880682 Direct Acting Antivirals for HCV Infection in Kidney Transplant Recipients https://ClinicalTrials.gov/show/NCT03880682 Completed Istanbul University 2019-06-15
NCT03868163 Real World Evidence of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C in the Russian Federation https://ClinicalTrials.gov/show/NCT03868163 Active, not recruiting AbbVie 2020-08-15
NCT03864263 Hepatitis B Virus Infection in Immunized Children With HBsAg-positive Parents https://ClinicalTrials.gov/show/NCT03864263 Recruiting Children’s Hospital of Chongqing Medical University 2020-12-31
NCT03865966 Hepatitis B Virus Infection After Liver Transplantation in Children https://ClinicalTrials.gov/show/NCT03865966 Recruiting Children’s Hospital of Chongqing Medical University 2023-12-31
NCT03850899 Alcoholic Hepatitis Network Observational Study https://ClinicalTrials.gov/show/NCT03850899 Recruiting Indiana University 2024-02-29
NCT03839979 HCV Viral Hepatitis, Blood Sugar Level and Systolic Blood Pressure in Egypt https://ClinicalTrials.gov/show/NCT03839979 Completed Cairo University 2018-12-31
NCT03777969 Prediction System of Clinical Endpoint Events for Chronic Hepatitis B Patients https://ClinicalTrials.gov/show/NCT03777969 Recruiting Beijing Friendship Hospital 2020-12-31
NCT03776760 Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination https://ClinicalTrials.gov/show/NCT03776760 Recruiting Kirby Institute 2022-02-28
NCT03740906 Direct-acting Antiviral Therapy and Reinfection Among People With Chronic Hepatitis C Virus Infection and Recent Injecting Drug Use in the Prison Setting https://ClinicalTrials.gov/show/NCT03740906 Recruiting Kirby Institute 2021-01-31
NCT03743272 Repeatability and Reproducibility of Multiparametric MRI https://ClinicalTrials.gov/show/NCT03743272 Recruiting Perspectum Diagnostics Ltd 2020-05-17
NCT03740230 An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs https://ClinicalTrials.gov/show/NCT03740230 Recruiting AbbVie 2022-09-30
NCT03711669 Biomarkers to Predict the Success of Immunosuppression Withdrawal in Autoimmune Hepatitis https://ClinicalTrials.gov/show/NCT03711669 Recruiting Hospital Clinic of Barcelona 2021-01-31
NCT03702998 Hepatocellular Carcinoma in HIV-infected Individuals in Asian Population https://ClinicalTrials.gov/show/NCT03702998 Recruiting Chinese University of Hong Kong 2020-07-31
NCT03697135 Ask a Friend to Take a Test for Hepatitis C Infection https://ClinicalTrials.gov/show/NCT03697135 Enrolling by invitation NHS Tayside 2019-12-30
NCT03692897 An Observational Study of Patients Undergoing Therapy for Chronic Hepatitis B (HBV) Infection https://ClinicalTrials.gov/show/NCT03692897 Active, not recruiting Target PharmaSolutions, Inc. 2023-01-31
NCT03693586 Study to Determine the Hepatitis C Virus Infection Prevalence Among Patients Attended Primarily for Vasculitis https://ClinicalTrials.gov/show/NCT03693586 Recruiting Hospital General de Mexico 2020-05-01
NCT03640728 The Efficacy and Safety of Nucleos(t)Ide Analogues in the Treatment of HBV-related Acute-on-chronic Liver Failure https://ClinicalTrials.gov/show/NCT03640728 Recruiting First Affiliated Hospital Xi’an Jiaotong University 2021-04-30
NCT03601221 Seroprevalence Hepatitis E Infection in Healthy Blood Donors https://ClinicalTrials.gov/show/NCT03601221 Completed Ente Ospedaliero Cantonale, Bellinzona 2018-12-31
NCT03570112 Transmission of Chronic Hepatitis C in Pregnancy https://ClinicalTrials.gov/show/NCT03570112 Recruiting The Christ Hospital 2020-06-30
NCT03559790 Treatment Efficacy and Safety of TDF-TAF Switch Study in South Korea https://ClinicalTrials.gov/show/NCT03559790 Recruiting The Catholic University of Korea 2020-08-31
NCT03564639 Examining Hepatitis C Reinfection Rates in Kenya https://ClinicalTrials.gov/show/NCT03564639 Enrolling by invitation Yale University 2020-11-30
NCT03551002 Impact of DAA Uptake in Controlling HCV Epidemic and Modeling Interventions for HCV Elimination Among HIV-infected Persons in San Diego https://ClinicalTrials.gov/show/NCT03551002 Recruiting University of California, San Diego 2020-12-31
NCT03529760 Chemotherapy Efficacy and Follow-up Study of Hepatitis B Virus Infection and Reactivation in Children With Leukemia https://ClinicalTrials.gov/show/NCT03529760 Recruiting Children’s Hospital of Chongqing Medical University 2019-07-15
NCT03524014 Hepatitis E Infection : Emergence Mechanisms in North-Eastern France of Polymorphic Clinical Forms. https://ClinicalTrials.gov/show/NCT03524014 Recruiting Central Hospital, Nancy, France 2019-06-30
NCT03511794 Effectiveness of the Hepatitis B Vaccine Post-Hematopoietic Stem Cell Transplant https://ClinicalTrials.gov/show/NCT03511794 Enrolling by invitation National Institutes of Health Clinical Center (CC) 2021-06-01
NCT03500562 Study of Daclatasvir-based Therapy in Chinese Participants With Chronic Hepatitis C (CHC) https://ClinicalTrials.gov/show/NCT03500562 Recruiting Bristol-Myers Squibb 2021-12-31
NCT03459768 Cohort Study on People Who Inject Drugs in Senegal https://ClinicalTrials.gov/show/NCT03459768 Active, not recruiting French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2020-02-29
NCT03425513 Hepatitis B Virus Prevalence and Risk Factors in Belgium https://ClinicalTrials.gov/show/NCT03425513 Completed Hasselt University 2017-11-27
NCT03426618 A Real-World Observational Study for the Safety and Efficacy of Baraclude in Korean Pediatric Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT03426618 Completed Bristol-Myers Squibb 2019-03-13
NCT03423641 An Observational Study of the Safety of Direct-acting Antivirals in Patients With Hepatitis C https://ClinicalTrials.gov/show/NCT03423641 Completed Kaiser Permanente 2017-12-31
NCT03415009 Prevalence of IL28B Polymorphism in Hepatitis C Patients https://ClinicalTrials.gov/show/NCT03415009 Completed Changi General Hospital 2016-06-30
NCT03413696 Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients https://ClinicalTrials.gov/show/NCT03413696 Enrolling by invitation University of California, San Diego 2019-12-31
NCT01264107 An Open Study to Evaluate the Sustained Effect in Patients Showing Virological Responses With Muscle-related Symptom of Chronic Hepatitis B Patients Who Received Clevudine https://ClinicalTrials.gov/show/NCT01264107 Completed Bukwang Pharmaceutical 2012-01-31
NCT01245257 Effects of Prednisolone and Pentoxifylline on the Regulation of Urea Synthesis in Alcoholic Hepatitis https://ClinicalTrials.gov/show/NCT01245257 Completed University of Aarhus 2015-06-30
NCT01200225 An Observational Study on The Impact of Insulin Resistance on Sustained Virological Response in Patients With Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) https://ClinicalTrials.gov/show/NCT01200225 Completed Hoffmann-La Roche 2013-06-30
NCT01163240 Epidemiological Study in Children and Adolescents With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01163240 Completed Novartis 2011-09-30
NCT01160081 Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis https://ClinicalTrials.gov/show/NCT01160081 Completed GlaxoSmithKline 2010-09-30
NCT01155427 Systematic Review of Antiretroviral Treatments for Chronic Hepatitis B (CHB) https://ClinicalTrials.gov/show/NCT01155427 Completed Bristol-Myers Squibb 2010-04-30
NCT01159951 Analysis of Trends Over Time of Hepatitis Related Incidence in Panama https://ClinicalTrials.gov/show/NCT01159951 Completed GlaxoSmithKline 2011-08-31
NCT01159925 Surveillance Study to Determine the Trends in Acute Hepatitis A Among Panamanian Children https://ClinicalTrials.gov/show/NCT01159925 Completed GlaxoSmithKline 2011-12-31
NCT01159613 Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection? https://ClinicalTrials.gov/show/NCT01159613 Completed Ziv Hospital 2008-10-31
NCT01128686 Lamivudine(LAM) Good Responder Study https://ClinicalTrials.gov/show/NCT01128686 Completed ViiV Healthcare 2011-06-30
NCT01107483 Observe Change of Endotoxaemia and Related Mediators in Patients With Chronic Hepatitis B Virus (HBV) Infection https://ClinicalTrials.gov/show/NCT01107483 Completed Sun Yat-sen University 2010-02-28
NCT01112033 Biliverdin Reductase A in Chronic Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT01112033 Completed Charles University, Czech Republic 2013-03-31
NCT01098097 Post Marketing Observational Study of Retreatment of Chronic Hepatitis C With Peginterferon Alpha and Ribavirin (Study P06011) https://ClinicalTrials.gov/show/NCT01098097 Completed Merck Sharp & Dohme Corp. 2011-10-31
NCT01090531 Patients With Chronic Hepatitis B and Low Viremia Not Receiving Antiviral Therapy https://ClinicalTrials.gov/show/NCT01090531 Active, not recruiting Johann Wolfgang Goethe University Hospital 2021-08-31
NCT01066819 PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b https://ClinicalTrials.gov/show/NCT01066819 Completed Hoffmann-La Roche 2011-08-31
NCT01070550 PROPHESYS 1: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Virus (HCV)Treated With Pegasys (Peginterferon Alfa-2a) https://ClinicalTrials.gov/show/NCT01070550 Completed Hoffmann-La Roche 2011-07-31
NCT01066793 PROPHESYS 2: An Observational Study on Predictors of Response in Treatment-naïve Patients With Chronic Hepatitis C Treated With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b https://ClinicalTrials.gov/show/NCT01066793 Completed Hoffmann-La Roche 2011-03-31
NCT01062321 Role of Cytokines in Hepatitis E Virus Infection During Pregnancy https://ClinicalTrials.gov/show/NCT01062321 Completed Maulana Azad Medical College 2012-07-31
NCT01054742 Observational Study of Patients With Chronic Hepatitis C Virus (HCV) Infected With HCV Genotype 1 Low Virus Load (LVL 1) and Effect of PegIntron Plus Rebetol Treatment (Study P04793 Part 2) https://ClinicalTrials.gov/show/NCT01054742 Completed Merck Sharp & Dohme Corp. 2011-06-30
NCT01033045 Epidemiological Study to Evaluate the Management of Patients With Chronic Hepatitis C and Previous Treatment Failure https://ClinicalTrials.gov/show/NCT01033045 Completed Fundacion IMIM 2013-07-31
NCT01011738 An Observational Cohort Study in Patients With Chronic Hepatitis B Receiving Pegasys https://ClinicalTrials.gov/show/NCT01011738 Completed Hoffmann-La Roche 2014-11-18
NCT00998621 ADHEPTA Study: Adherence Questionnaire in Hepatitis C https://ClinicalTrials.gov/show/NCT00998621 Completed Fundacion IMIM 2010-09-30
NCT00979979 Clinical Performance of Abbott RealTime Hepatitis C Virus (HCV) Genotype II Test https://ClinicalTrials.gov/show/NCT00979979 Completed National Taiwan University Hospital 2013-10-31
NCT00970216 Study of Telbivudine in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00970216 Completed Chang Gung Memorial Hospital 2016-01-31
NCT00946010 Investigation of Hepatitis B and Hepatitis C in Taiwan https://ClinicalTrials.gov/show/NCT00946010 Completed National Taiwan University Hospital 2010-08-31
NCT00881036 Activation of Hepatitis B Virus (HBV) in Hepatitis B Surface Antigen (HBsAg) - Negative But Hepatitis B Core Antibody (Anti-HBc) - Positive Patients https://ClinicalTrials.gov/show/NCT00881036 Completed Kyoto University 2015-07-31
NCT00876148 Risk of Hepatitis B Virus Reactivation in Patients Undergoing Allografting https://ClinicalTrials.gov/show/NCT00876148 Completed Azienda Ospedaliera San Giovanni Battista NA
NCT00863109 Quality of Life During Treatment of Chronic Hepatitis C (P05278/MK-4031-336) https://ClinicalTrials.gov/show/NCT00863109 Completed Merck Sharp & Dohme Corp. 2013-05-31
NCT04088370 Peripheral Blood Mononuclear Cells Response In Healthy Controls, Heavy Drinkers, and Patients With Alcoholic Hepatitis https://ClinicalTrials.gov/show/NCT04088370 Recruiting The Cleveland Clinic 2021-09-30
NCT01581554 Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01581554 Completed National Institutes of Health Clinical Center (CC) NA
NCT04366973 A Study Describing the Care Cascade and Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adult Participants With Hepatitis C Virus in French Addiction Centers https://ClinicalTrials.gov/show/NCT04366973 Recruiting AbbVie 2022-09-30
NCT04036760 Implementation and Evaluation of Care Coordination in Linkage to Care for Hepatitis C Following Release From New York City Jails https://ClinicalTrials.gov/show/NCT04036760 Completed NYU Langone Health 2017-04-30
NCT01416610 An Observational Study of Pegasys (Peginterferon Alfa-2a) Plus Copegus (Ribavirin) in Participants With Chronic Hepatitis C (CHC), Genotype 2, 3, 1 or 4, Undergoing Opioid Maintenance Therapy https://ClinicalTrials.gov/show/NCT01416610 Completed Hoffmann-La Roche 2014-10-31
NCT01957085 Undiagnosed Hepatitis C Infection in an Urban Hospital https://ClinicalTrials.gov/show/NCT01957085 Completed Temple University 2015-12-31
NCT02005146 Retrospective Observational Study to Define HBsAg Loss With or Without Seroconversion to antiHBs in Patients With Chronic Hepatitis by B Virus Treated With Nucleoside/Nucleotide Analogs https://ClinicalTrials.gov/show/NCT02005146 Completed Andalusian Network for Design and Translation of Advanced Therapies 2014-12-31
NCT01337479 A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials https://ClinicalTrials.gov/show/NCT01337479 Completed Bristol-Myers Squibb 2010-09-30
NCT01182311 Duration of Long-term Immunity After Hepatitis B Virus Immunization https://ClinicalTrials.gov/show/NCT01182311 Completed National Institutes of Health Clinical Center (CC) NA
NCT03510637 “Real Life” Evaluation of Efficacy and Safety of Direct Antiviral Agents (DAAs) for the Treatment of Hepatitis C Virus in Egypt https://ClinicalTrials.gov/show/NCT03510637 Recruiting French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS) 2020-08-31
NCT02850289 APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin https://ClinicalTrials.gov/show/NCT02850289 Completed Hoffmann-La Roche 2008-10-31
NCT02581163 Effectiveness of Paritaprevir/Ritonavir - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C - An Observational Study in Belgium https://ClinicalTrials.gov/show/NCT02581163 Completed AbbVie 2018-02-12
NCT02581020 The Durability of Response and Persistence of Resistance to AbbVie’s 2 Direct-acting Antiviral Agent (2D) Therapy in Japanese Subjects https://ClinicalTrials.gov/show/NCT02581020 Active, not recruiting AbbVie 2020-12-31
NCT02515279 An Observational Study of Peginterferon Alfa-2a Plus Ribavirin for Hepatitis C Virus (HCV) Infection in Austria https://ClinicalTrials.gov/show/NCT02515279 Completed Hoffmann-La Roche 2014-12-31
NCT02443233 Evaluation of Paternal, Maternal and Obstetric Factors Leading to the Hepatitis B Immunization Failure in Hong Kong https://ClinicalTrials.gov/show/NCT02443233 Completed The University of Hong Kong 2016-12-31
NCT01959321 An Observational Study of Hepatitis C Virus in Pregnancy https://ClinicalTrials.gov/show/NCT01959321 Active, not recruiting The George Washington University Biostatistics Center 2020-12-31
NCT01734018 An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01734018 Completed Hoffmann-La Roche 2012-08-31
NCT03181113 Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy https://ClinicalTrials.gov/show/NCT03181113 Enrolling by invitation Xiamen Amoytop Biotech Co., Ltd. 2020-12-31
NCT00913757 A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area https://ClinicalTrials.gov/show/NCT00913757 Completed National Institutes of Health Clinical Center (CC) 2020-05-01
NCT00782158 Hepatitis B and HIV Co-Infection in Patients in Uganda https://ClinicalTrials.gov/show/NCT00782158 Completed National Institutes of Health Clinical Center (CC) NA
NCT00769730 Evaluation the Possible Influence of Transcatheter Arterial Chemoembolization on Hepatitis B Viral Replication https://ClinicalTrials.gov/show/NCT00769730 Completed Kaohsiung Medical University Chung-Ho Memorial Hospital 2009-02-28
NCT00736242 Post-marketing Surveillance of HIV-infected Patients With Chronic Hepatitis C Treated With PegIntron Pen and Rebetol (Study P04584) https://ClinicalTrials.gov/show/NCT00736242 Completed Merck Sharp & Dohme Corp. 2011-12-31
NCT00727311 Real-life Surveillance Study of Patients With Chronic Hepatitis C Treated With PegIntron Injector and Rebetol (Study P04538)(COMPLETED) https://ClinicalTrials.gov/show/NCT00727311 Completed Merck Sharp & Dohme Corp. 2009-06-30
NCT00728494 Compliance of HCV Genotype 1 Infected Patients Receiving PegIntron/Rebetol and a Patient Assistance Program (Study P04671) https://ClinicalTrials.gov/show/NCT00728494 Completed Merck Sharp & Dohme Corp. 2007-12-31
NCT00725751 Treatment of Chronic Hepatitis C With Pegylated Interferon and Ribavirin in Participants With/Without Substitution Therapy (P05255) https://ClinicalTrials.gov/show/NCT00725751 Completed Merck Sharp & Dohme Corp. 2011-03-31
NCT00726557 Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261) https://ClinicalTrials.gov/show/NCT00726557 Completed Merck Sharp & Dohme Corp. 2009-01-31
NCT00725205 Patient Compliance During PegIntron and Rebetol Combination Therapy in Chronic Hepatitis C (Study P04690) https://ClinicalTrials.gov/show/NCT00725205 Completed Merck Sharp & Dohme Corp. 2010-10-31
NCT00724893 Efficacy of Pegetron® Redipen™ Treatment and Treatment Compliance of Patients With Chronic Hepatitis C in Canada (P04423) https://ClinicalTrials.gov/show/NCT00724893 Completed Merck Sharp & Dohme Corp. 2012-08-31
NCT00724854 Evaluation of Rapid Virologic Response Among HCV Patients Treated With PegIntron and Rebetol in Brazil (Study P05427) https://ClinicalTrials.gov/show/NCT00724854 Completed Merck Sharp & Dohme Corp. 2009-09-30
NCT00724295 Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505) https://ClinicalTrials.gov/show/NCT00724295 Completed Merck Sharp & Dohme Corp. 2008-12-31
NCT00724464 Efficacy of PegIntron (Peginterferon Alfa-2b) and Rebetol (Ribavirin) in Treatment-naïve Subjects With Chronic Hepatitis C in Clinical Practice in Greece (Study P05209) https://ClinicalTrials.gov/show/NCT00724464 Completed Merck Sharp & Dohme Corp. 2010-10-31
NCT00724230 Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED) https://ClinicalTrials.gov/show/NCT00724230 Completed Merck Sharp & Dohme Corp. 2008-12-31
NCT00724451 Observational Study Assessing Chronic Hepatitis C Management in Clinical Practice in Italy (Study P05488 AM1) https://ClinicalTrials.gov/show/NCT00724451 Completed Merck Sharp & Dohme Corp. 2011-10-31
NCT00723892 Adherence in Patients Receiving PegIntron/Rebetol for Hepatitis C in Conjunction With a Psychotherapy Support Program (Study P04252) https://ClinicalTrials.gov/show/NCT00723892 Completed Merck Sharp & Dohme Corp. 2009-05-31
NCT00723632 Pharmacoeconomic Study Assessing the Cost of Chronic Hepatitis C Treatment With Peginterferon Alfa-2b (PegIntron) and Ribavirin (Rebetol) in the Czech Republic (Study P04588)(COMPLETED) https://ClinicalTrials.gov/show/NCT00723632 Completed Merck Sharp & Dohme Corp. 2010-12-31
NCT00710801 Assessment of Biomarkers for Recurrent HCV Infection Post-liver Transplantation https://ClinicalTrials.gov/show/NCT00710801 Completed University of Alberta NA
NCT00709228 Study of Patients With Chronic Hepatitis C Infected With HCV LVL G1 and Effect of Peg-Intron Plus Rebetol Treatment (Study P04793) https://ClinicalTrials.gov/show/NCT00709228 Completed Merck Sharp & Dohme Corp. 2008-11-30
NCT00709059 Efficacy of PegIntron and Rebetol in Previously Untreated Patients With Chronic Hepatitis C Infected With HCV Genotype 1/4/5/6 (Study P04243) https://ClinicalTrials.gov/show/NCT00709059 Completed Merck Sharp & Dohme Corp. 2009-12-31
NCT00705666 Treatment of Patients With Chronic Hepatitis C With PegIntron as Monotherapy or in Combination With Ribavirin (Study P04437)(COMPLETED) https://ClinicalTrials.gov/show/NCT00705666 Completed Merck Sharp & Dohme Corp. 2008-07-31
NCT00707603 Chronic Hepatitis C and Insulin Resistance https://ClinicalTrials.gov/show/NCT00707603 Completed Garvan Institute of Medical Research 2008-12-31
NCT00705263 Satisfaction in Patients Receiving the PegIntron Pen Plus Rebetol for Hepatitis C (Study P04244)(COMPLETED) https://ClinicalTrials.gov/show/NCT00705263 Completed Schering-Plough 2008-05-31
NCT00704964 Impact of Patient Support by the Medical Staff on Adherence to Therapy With PegIntron Plus Rebetol (Study P04413) https://ClinicalTrials.gov/show/NCT00704964 Completed Merck Sharp & Dohme Corp. 2009-10-31
NCT00705224 Effect of Insulin Resistance on the Safety and Efficacy of Pegylated Interferon and Ribavirin Treatment in HCV (Study P05562) https://ClinicalTrials.gov/show/NCT00705224 Completed Merck Sharp & Dohme Corp. 2010-08-31
NCT00704717 Evaluation of Patient Satisfaction in Hepatitis C Patients Treated With PegIntron Pen and Rebetol in Romania (Study P04301) https://ClinicalTrials.gov/show/NCT00704717 Completed Merck Sharp & Dohme Corp. 2007-12-31
NCT00704522 Adherence in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C in Conjunction With a Patient Assistance Program (Study P04281)(COMPLETED) https://ClinicalTrials.gov/show/NCT00704522 Completed Merck Sharp & Dohme Corp. 2009-04-30
NCT00703560 Study of Hepatitis C Virus (HCV) Viral Kinetics in HIV/HCV and HCV Patients https://ClinicalTrials.gov/show/NCT00703560 Completed University of Texas Southwestern Medical Center 2011-09-30
NCT00700401 POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin). https://ClinicalTrials.gov/show/NCT00700401 Completed Hoffmann-La Roche 2010-11-30
NCT00674492 Hepatitis C Virus (HCV) Treatment Completion or Withdrawal https://ClinicalTrials.gov/show/NCT00674492 Completed VA Office of Research and Development 2008-08-31
NCT00659256 Hepatitis C Treatment and Atherosclerosis https://ClinicalTrials.gov/show/NCT00659256 Completed National Institutes of Health Clinical Center (CC) NA
NCT00645736 CHARM: Chronic Hepatitis B Antihepadnaviral Resistance Mutation Study https://ClinicalTrials.gov/show/NCT00645736 Completed Gilead Sciences 2008-10-31
NCT00606528 FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy https://ClinicalTrials.gov/show/NCT00606528 Completed University Health Network, Toronto 2013-07-31
NCT00527774 Effect of HCV Infection on Insulin Resistance and Malnutrition-inflammation Complex Syndrome in Regular Hemodialysis Patients https://ClinicalTrials.gov/show/NCT00527774 Completed St. Martin De Porress Hospital 2008-02-29
NCT00512941 Laboratory Profile of Hepatitis B and C in Users of a Reference Service https://ClinicalTrials.gov/show/NCT00512941 Completed UPECLIN HC FM Botucatu Unesp NA
NCT00514111 Factors Associated to Success of Hepatitis C Therapy https://ClinicalTrials.gov/show/NCT00514111 Completed UPECLIN HC FM Botucatu Unesp 2008-07-31
NCT00494936 Effects of HIV and Hepatitis C Virus on the Brain https://ClinicalTrials.gov/show/NCT00494936 Completed Icahn School of Medicine at Mount Sinai 2009-07-31
NCT00473993 Hepatitis C Among Opioid Addicts in Opioid Maintenance Treatment in Zurich, Switzerland https://ClinicalTrials.gov/show/NCT00473993 Completed Seidenberg, Arztpraxis A., M.D. NA
NCT00466336 Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices https://ClinicalTrials.gov/show/NCT00466336 Completed National Taiwan University Hospital 2006-12-31
NCT00444002 Oxidative Stress and Fatty Acids in Hepatitis C https://ClinicalTrials.gov/show/NCT00444002 Completed University Health Network, Toronto 2008-07-31
NCT00422838 Study Investigating Immunological Effects of Treatment for Chronic Hepatitis C Patients. https://ClinicalTrials.gov/show/NCT00422838 Completed Foundation for Liver Research 2010-06-30
NCT00388674 Study of Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection https://ClinicalTrials.gov/show/NCT00388674 Completed Bristol-Myers Squibb 2016-10-26
NCT00381992 Risk Assessment of Long-Haul Truck Drivers https://ClinicalTrials.gov/show/NCT00381992 Completed Wake Forest University Health Sciences 2010-03-31
NCT00342641 Association Between Hepatitis C Virus Infection and Hematologic and Thyroid Cancers https://ClinicalTrials.gov/show/NCT00342641 Completed National Institutes of Health Clinical Center (CC) NA
NCT00368225 Transplant-Related Accelerated Progression of Hepatitis C https://ClinicalTrials.gov/show/NCT00368225 Completed National Institutes of Health Clinical Center (CC) NA
NCT00361179 Long Term Effects of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/B Co-Infection and Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00361179 Completed National Taiwan University Hospital NA
NCT00348660 Screening for Hepatitis C During Pregnancy at a Toronto Inner City Prenatal Clinic https://ClinicalTrials.gov/show/NCT00348660 Completed St. Michael’s Hospital, Toronto 2010-10-31
NCT00342186 Genes Involved in Resistance or Susceptibility to Hepatitis B Virus https://ClinicalTrials.gov/show/NCT00342186 Completed National Institutes of Health Clinical Center (CC) 2018-02-22
NCT00322179 Microarray Analysis of IFN-Induced Gene Expression in Obese and Non-Obese Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00322179 Completed Palo Alto Veterans Institute for Research 2007-11-30
NCT00237991 Safety of GlaxoSmithKline (GSK) Biologicals Hepatitis A Vaccine in Korean Population https://ClinicalTrials.gov/show/NCT00237991 Completed GlaxoSmithKline NA
NCT00237432 Study of the Immune Response to Hepatitis C Virus https://ClinicalTrials.gov/show/NCT00237432 Completed Rockefeller University NA
NCT00227149 Long-Term Evaluation Follow-up of Neurocognitive Performance and Emotional State in Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00227149 Completed University of Wuerzburg NA
NCT00219999 Hepatitis C Virus and the Humoral Immune System https://ClinicalTrials.gov/show/NCT00219999 Completed Rockefeller University 2013-05-31
NCT00216775 Comparative Trial of Standard Versus Low-dose Peg-Interferon Plus Ribavirin in the Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT00216775 Completed Kyoto University 2008-05-31
NCT00205075 Impact of Moderate Alcohol Use on Hepatitis C Virus (HCV) Progression https://ClinicalTrials.gov/show/NCT00205075 Completed University of Wisconsin, Madison 2008-06-30
NCT00199732 Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a https://ClinicalTrials.gov/show/NCT00199732 Completed University Hospital, Limoges 2009-07-31
NCT00187473 Natural History of Hepatitis C in Patients With Normal Liver Tests https://ClinicalTrials.gov/show/NCT00187473 Active, not recruiting University of California, San Francisco 2020-12-31
NCT00168194 Cellular Immune Responses to Hepatitis B Virus (HBV)- Longitudinal Follow up and Natural History https://ClinicalTrials.gov/show/NCT00168194 Completed The Alfred NA
NCT00158717 Observational Study of the Durability of Seroconversion Chronic HBV Patients Who Seroconverted in a Previous Gilead-Sponsored Study of ADV. https://ClinicalTrials.gov/show/NCT00158717 Completed Gilead Sciences 2006-04-30
NCT00155155 Studies of Immune Responses in Patients With Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT00155155 Completed National Taiwan University Hospital 2008-04-30
NCT00150904 Peginterferon and Ribavirin on Virologic and Immunologic Parameters in Hepatitis C Mono- and Coinfected Patient (PRIVICOP) https://ClinicalTrials.gov/show/NCT00150904 Completed UMC Utrecht 2008-09-30
NCT00142740 Hepatitis B Vaccine Genetics: A Substudy of ATN 024 and ATN 025 https://ClinicalTrials.gov/show/NCT00142740 Completed University of North Carolina, Chapel Hill 2008-06-30
NCT00141999 Response to Booster Doses of Hepatitis B Vaccine in Children and Adolescents https://ClinicalTrials.gov/show/NCT00141999 Completed Centers for Disease Control and Prevention 2005-03-31
NCT00136214 Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects https://ClinicalTrials.gov/show/NCT00136214 Completed Beth Israel Deaconess Medical Center 2008-01-31
NCT00097006 Retrovirus Epidemiology Donor Study-II (REDS-II) https://ClinicalTrials.gov/show/NCT00097006 Completed National Heart, Lung, and Blood Institute (NHLBI) 2009-09-30
NCT00076427 Leukapheresis for Research on HCV-Coinfected Patients https://ClinicalTrials.gov/show/NCT00076427 Completed National Institutes of Health Clinical Center (CC) NA
NCT00071916 Racial Difference in HCV/Host Interactions https://ClinicalTrials.gov/show/NCT00071916 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00819026 Observational Trial of Hepatitis C Virus Infected Patients on Calcineurin Inhibitors https://ClinicalTrials.gov/show/NCT00819026 Completed University of Wisconsin, Madison 2013-08-31
NCT00059397 Hepatitis C: Grading and Staging by MR https://ClinicalTrials.gov/show/NCT00059397 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NA
NCT00059267 Prevention of Recurrent Hepatitis B After Liver Transplantation https://ClinicalTrials.gov/show/NCT00059267 Completed National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 2007-11-30
NCT00001879 Collections of Blood and Stool Samples in Patients With Acute Hepatitis https://ClinicalTrials.gov/show/NCT00001879 Completed National Institutes of Health Clinical Center (CC) NA
NCT00004848 A Controlled Prospective Study of Transfusion-Associated Hepatitis https://ClinicalTrials.gov/show/NCT00004848 Completed National Institutes of Health Clinical Center (CC) NA
NCT00001982 History of Hepatitis C in Volunteer Blood Donors https://ClinicalTrials.gov/show/NCT00001982 Completed National Institutes of Health Clinical Center (CC) NA
NCT00037076 Prevalence of Hepatitis C Virus Infection in HIV-Infected Children https://ClinicalTrials.gov/show/NCT00037076 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00727259 Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) https://ClinicalTrials.gov/show/NCT00727259 Completed Merck Sharp & Dohme Corp. 2008-04-30
NCT00006643 Comparing Single Photon Emission Computed Tomography (SPECT) and Liver Biopsy to Evaluate the Liver in Patients With HIV and Hepatitis C Virus https://ClinicalTrials.gov/show/NCT00006643 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00001117 A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection https://ClinicalTrials.gov/show/NCT00001117 Completed National Institute of Allergy and Infectious Diseases (NIAID) NA
NCT00723645 Rate and Predictors of Relapse in the Treatment of Hepatitis C (Study P05181) https://ClinicalTrials.gov/show/NCT00723645 Completed Merck Sharp & Dohme Corp. 2010-04-30
NCT00006301 Immune Response to Hepatitis C Virus https://ClinicalTrials.gov/show/NCT00006301 Completed National Institutes of Health Clinical Center (CC) NA
NCT00007709 To Determine the Prevalence of HIV and Other Related Infections Such as Hepatitis C, Along With Associated Risk Behaviors, in Patients With Severe Mental Illness (SMI). https://ClinicalTrials.gov/show/NCT00007709 Completed VA Office of Research and Development NA
NCT00007371 Hepatitis C in Clinically Discordant Hemophilic Siblings https://ClinicalTrials.gov/show/NCT00007371 Completed University of North Carolina, Chapel Hill 2004-08-31
NCT00005306 Natural History of Post-transfusion Non-A, Non-B Hepatitis https://ClinicalTrials.gov/show/NCT00005306 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005339 Risk of Post Transfusion Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT00005339 Completed National Heart, Lung, and Blood Institute (NHLBI) NA
NCT00005305 Hepatitis Delta Infections in Hemophiliacs https://ClinicalTrials.gov/show/NCT00005305 Completed University of North Carolina, Chapel Hill 1991-09-30
NCT00005657 Genetics of Hepatitis C Virus Infection https://ClinicalTrials.gov/show/NCT00005657 Completed National Institutes of Health Clinical Center (CC) NA
NCT00005304 Delta Hepatitis and Liver Disease in Hemophiliacs https://ClinicalTrials.gov/show/NCT00005304 Completed Baylor College of Medicine NA
NCT00001712 Frequency of Parenteral and Non-Parenteral Exposures to Blood Among Healthcare Workers at the Clinical Center, NIH and at Seven Academic Hospitals in Japan https://ClinicalTrials.gov/show/NCT00001712 Completed National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03108794 A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B https://ClinicalTrials.gov/show/NCT03108794 Recruiting Beijing Friendship Hospital 2022-12-31
NCT03025074 Blood Collection Biorepository for Liver Disease Research https://ClinicalTrials.gov/show/NCT03025074 Recruiting State University of New York at Buffalo 2099-12-31
NCT02971488 The Impact on Linkage-to-care of an Alternative Hepatitis C Screening Method in PWID https://ClinicalTrials.gov/show/NCT02971488 Completed Hospital Universitario Infanta Leonor 2018-12-31
NCT02969668 Interferon-free Antiviral Treatment of Chronic Hepatitis C Virus Infection Among Opioid-substituted Patients https://ClinicalTrials.gov/show/NCT02969668 Active, not recruiting Universitätsklinikum Hamburg-Eppendorf 2018-10-31
NCT01962155 Prospective Stuy in Evaluating Hepatic Fibrosis Related to Hepatitis B Virus Using Non-invasive Parameters https://ClinicalTrials.gov/show/NCT01962155 Completed Peking University First Hospital 2015-12-31
NCT02699736 EuroSIDA - Clinical and Virological Outcome of European Patients Infected With HIV https://ClinicalTrials.gov/show/NCT02699736 Enrolling by invitation Rigshospitalet, Denmark 2030-12-31
NCT02766933 Cameroon Baptist Convention Health Board Chronic Hepatitis B Cohort Study https://ClinicalTrials.gov/show/NCT02766933 Active, not recruiting Mayo Clinic 2022-05-31
NCT02510300 A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials https://ClinicalTrials.gov/show/NCT02510300 Enrolling by invitation Gilead Sciences 2024-11-30
NCT02375906 The Hepatitis Delta International Network https://ClinicalTrials.gov/show/NCT02375906 Recruiting HepNet Study House, German Liverfoundation 2020-12-31
NCT02292706 A Registry for Participants With Cirrhosis Who Achieve a Sustained Virologic Response Following Treatment With a Sofosbuvir-Based Regimen Without Interferon for Chronic Hepatitis C Infection https://ClinicalTrials.gov/show/NCT02292706 Active, not recruiting Gilead Sciences 2023-01-31
NCT02263755 Establishment of Retrospective and Prospective Multicenter Cohort for Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT02263755 Completed Yonsei University 2015-06-25
NCT02250001 Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT02250001 Completed Bristol-Myers Squibb 2017-01-20
NCT02031913 Prospective Cohort Study of Association of Insulin Resistance/Steatosis With Hepatic Fibrosis in CHB and NAFLD https://ClinicalTrials.gov/show/NCT02031913 Recruiting Seoul National University Boramae Hospital 2022-11-30
NCT02025842 Hepatitis B Virus HBeAg-negative Genotype D Patients and Hepatocellular Carcinoma https://ClinicalTrials.gov/show/NCT02025842 Completed Azienda Ospedaliera San Camillo Forlanini 2013-12-31
NCT01908660 Hepatic Safety of Currently Used Antiretroviral Regimens in Patients With Chronic Hepatitis Under Real Life Conditions https://ClinicalTrials.gov/show/NCT01908660 Completed Valme University Hospital 2015-09-30
NCT01846494 Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C) https://ClinicalTrials.gov/show/NCT01846494 Completed Duke University 2018-03-19
NCT01679769 Prospective Study In Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis B https://ClinicalTrials.gov/show/NCT01679769 Completed Peking University First Hospital 2015-10-31
NCT01590615 Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy https://ClinicalTrials.gov/show/NCT01590615 Completed Gilead Sciences 2017-04-04
NCT04301882 An Observational Cohort Study of Clinical Outcomes After Antiviral Treatment of Chronic Hepatitis C https://ClinicalTrials.gov/show/NCT04301882 Recruiting Beijing Ditan Hospital 2020-09-01
NCT04142723 Alcoholic Hepatitis in Latin-America: A Prospective and Multicentric Study (AH-LATIN). https://ClinicalTrials.gov/show/NCT04142723 Recruiting Pontificia Universidad Catolica de Chile 2022-06-20
NCT04106518 Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease https://ClinicalTrials.gov/show/NCT04106518 Recruiting University Hospital, Lille 2022-10-31
NCT04065230 Study of Tenofovir Alafenamide Fumarate Tablets (TAF) in Blocking Mother-to-child Transmission of Hepatitis B Virus https://ClinicalTrials.gov/show/NCT04065230 Recruiting Southeast University, China 2021-08-31
NCT04062253 Addressing the Cascade of Care in Vulnerable Populations With Poor Access to Healthcare in Madrid https://ClinicalTrials.gov/show/NCT04062253 Recruiting Hospital Universitario Infanta Leonor 2020-02-15
NCT04025944 Real World Study of Chronic Viral Hepatitis https://ClinicalTrials.gov/show/NCT04025944 Recruiting Huashan Hospital 2024-08-01
NCT03680183 Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV) https://ClinicalTrials.gov/show/NCT03680183 Recruiting Affiliated Cancer Hospital & Institute of Guangzhou Medical University 2019-03-01
NCT03619590 Twinrix Pregnancy Registry https://ClinicalTrials.gov/show/NCT03619590 Completed GlaxoSmithKline 2017-09-15
NCT03587714 Prevalence of Hepatitis c Virus Infection Among Rheumatological Patients https://ClinicalTrials.gov/show/NCT03587714 Completed Assiut University 2017-12-01
NCT03566966 Autoantibodies and Direct-acting Antivirals https://ClinicalTrials.gov/show/NCT03566966 Completed University of Bari 2016-08-31
NCT03146884 Swiss Autoimmune Hepatitis Cohort Study https://ClinicalTrials.gov/show/NCT03146884 Recruiting Fondazione Epatocentro Ticino 2022-12-31
NCT03226509 Transforming the Cascade Of Hepatitis C Care https://ClinicalTrials.gov/show/NCT03226509 Active, not recruiting University of Pittsburgh 2019-09-30
NCT04139850 The Establishment of Korean Hepatitis B Patients Cohort https://ClinicalTrials.gov/show/NCT04139850 Recruiting Yonsei University 2026-08-31